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ABSTRACT OF THE DISSERTATION
Mechanisms of Post-hemorrhagic Hydrocephalus after Germinal Matrix Hemorrhage
by
Damon William Klebe
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, June 2016
Dr. John H. Zhang, Chairperson

The inherently fragile vasculature of the germinal matrix is susceptible to rupture,
possibly as a result of hemodynamic and cardiorespiratory instability associated with
prematurity. Germinal matrix hemorrhage is a leading cause of morbidity and mortality
in preterm and/or very low birthweight infants, and post-hemorrhagic hydrocephalus is
major consequence of severe grade hemorrhages. Chronic post-hemorrhagic
hydrocephalus treatment involves surgical insertion of shunts, which are costly and prone
to complications. Thus, a safe non-invasive therapeutic approach towards posthemorrhagic hydrocephalus clinical management would significantly improve the quality
of life for this patient population. Thrombin, cerebroventricular blood clots, and iron have
been identified as causative factors of hydrocephalus formation. Thrombin stimulates
proteinase-activated receptors, leading to subsequent mTOR activation and extracellular
matrix protein proliferation, which possibly obstruct the cerebroventricular system. Blood
clots may directly impair cerebrospinal fluid circulation and absorption. PPARγ
stimulation enhances micgroglial/macrophage phagocytosis of erythrocytes via CD36
scavenger receptor, augmenting clot resolution and improving outcomes after adult
cerebral hemorrhage. Additionally, lysed erythrocytes and metabolized hemoglobin
release iron, which is associated with brain injury after adult cerebral hemorrhage and
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contribute to post-hemorrhagic hydrocephalus development. The central aim of this
proposal is to determine the role of activated thrombin/PAR-1/mTOR pathway as well as
the role of hematoma resolution by PPARγ/CD36 and iron chelation by Deferoxamine in
hydrocephalus development after germinal matrix hemorrhage. Direct thrombin
inhibition reduced short-term mTOR activation and ameliorated long-term posthemorrhagic hydrocephalus development, neurocogntive deficits, and extracellular
matrix protein proliferation, although PAR-1 inhibition alone did not achieve the same
therapeutic benefits. PPARγ stimulation improved short-term hematoma resolution,
which was reversed by PPARγ antagonism and CD36 knockdown. PPARγ stimulation
attenuated long-term neurocognitive deficits and post-hemorrhagic hydrocephalus, which
was reversed by PPARγ antagonism. Acute and delayed iron chelation also reduced longterm post-hemorrhagic hydrocephalus development, neurocognitive deficits, and
extracellular matrix protein proliferation. Thus, thrombin/PAR/mTOR pathway
inhibition, enhanced PPARγ/CD36 mediated hematoma resolution, and iron chelation
significantly ameliorated short and long-term brain sequelae after germinal matrix
hemorrhage and are clinically viable therapeutic targets warranting further investigation.
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Abstract
In addition to being the leading cause of morbidity and mortality in premature
infants, germinal matrix hemorrhage (GMH) is also the leading cause of acquired
infantile hydrocephalus. The pathophysiology of post-hemorrhagic hydrocephalus
development after GMH is complex and vaguely understood, although evidence suggests
fibrosis and gliosis in the periventricular and subarachnoid spaces disrupts normal
cerebrospinal fluid dynamics. Theories explaining general hydrocephalus etiology have
substantially evolved from the original bulk flow theory developed by Dr. Dandy over a
century ago. Current clinical and experimental evidence supports a new hydrodynamic
theory for hydrocephalus development involving redistribution of vascular pulsations and
disruption of starling forces in the brain microcirculation. In this review, we discuss
cerebrospinal fluid flow dynamics, history and development of theoretical hydrocephalus
pathophysiology, and GMH epidemiology and etiology as it relates to post-hemorrhagic
hydrocephalus development. We highlight known mechanisms and propose new avenues
that will further elucidate GMH pathophysiology, specifically related to hydrocephalus.
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Introduction
Germinal matrix hemorrhage (GMH) occurs in approximately 3 live births per
1,000, has a 20-30% mortality rate, and accounts for 1.7% of all neonatal deaths in the
United States (Ballabh 2014; Osterman, Kochanek et al. 2015). Premature infants have a
much higher rate of occurrence; for infants born before 32 weeks of gestation up to 20%,
(about 12,000 infants) develop GMH each year in the US (Kochanek, Kirmeyer et al.
2012). Fortunately, the premature birthrate and percentage of low birthweight (<2500g)
infants have steadily declined between 2006 and 2013, although remaining higher than in
the 1980s and 1990s. In 2013, the preterm birthrate was 11.39% and the percentage of
low birthweight infants was 8.02%. The percentage of very low birthweight (<1500g)
was 1.41% in 2013 (Osterman, Kochanek et al. 2015). A study investigating premature
infants dating back to 1914 determined median postnatal survival increased from 2 to 26
days, and median gestational age decreased from 33 to 27 weeks. Interestingly, GMH
incidence was 4.7% before 1960, but it increased to 50.0% between 1975 and 1980, and
then decreased to 12.5% after 2005 (Hefti, Trachtenberg et al. 2015). The introduction of
positive pressure ventilation in preterm clinical management after the 1960s increased
survival while simultaneously increasing GMH incidence, which may be attributed to
cardiorespiratory and hemodynamic instability associated with mechanical ventilation,
and the decline in GMH incidence after the 1980s may be attributed to improvements in
mechanical ventilation methodology as well as the use of antenatal steroids and
surfactant. Despite improving trends in premature birth incidences and outcomes, GMH
remains the leading cause of morbidity and mortality in premature and/or very low
birthweight infants, and its incidence has remained steady in the past decade.
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Premature and very low birthweight infants are prone to hemodynamic and
cardiorespiratory instability, leading to abrupt fluctuations in cerebral blood flow
(Ballabh 2014). The fetal brain is hypothesized to lack vascular autoregulatory
mechanisms to adequately respond to cerebral blood flow fluctuations, although clinical
research involving cerebral blood flow monitoring in preterm infants has produced
ambiguous results (Tsuji, Saul et al. 2000; Soul, Hammer et al. 2007; du Plessis 2008;
Wong, Leung et al. 2008; Caicedo, De Smet et al. 2011; Alderliesten, Lemmers et al.
2013). The germinal matrix layer, which is present in the fetus and matures by term,
contains many neuronal and glial precursor cells and is a site of rapid angiogenesis
relative to other parts of the brain (Ballabh, Braun et al. 2004; Ballabh, Xu et al. 2007).
The germinal neurovascular unit, consisting of neurons, astrocytes, pericytes, vascular
smooth muscle cells, and vascular endothelial cells, is deficient in fibronectin at the
endothelial basal lamina, glial fibrillary acidic protein at astrocyte end-feed, and pericyte
coverage (Ballabh 2010; Ballabh 2014). Thus, the germinal matrix vasculature is
inherently weak and vulnerable to hemorrhage under abnormal conditions, regardless if
the premature infant brain has autoregulatory mechanisms to adequately respond to
cerebral blood flow fluctuations.
GMH severity is graded on an I-IV scale based on the extent and localization of
bleeding. Incidence of higher GMH grades (III-IV) increases as gestational age and/or
birthweight decreases (Robinson 2012). Between 50-75% of GMH survivors develop
long-term neurocognitive sequelae, including cerebral palsy, learning disabilities,
psychiatric disorders, and post-hemorrhagic hydrocephalus (PHH), and higher-grade
GMH survivors are most vulnerable to worse long-term outcomes (Ballabh 2010; Ballabh
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2014). The mortality rate for severe grade (III-IV) GMH is approximately 44%, with
60% of survivors developing PHH and 25% requiring surgical installation of shunts
(Vassilyadi, Tataryn et al. 2009). Another study estimates 10% of GMH patients (any
grade) and 20% of severe GMH patients (III-IV) will require surgical insertion of
permanent shunts (Robinson 2012). Shunt dependency is not desirable, given the large,
costly, detrimental complications that occur due to shunt infection, occlusion, and
displacement. Additional approaches to manage or prevent PHH include serial lumbar
punctures, ventricular taps, external ventricular drainage, ventricular access device,
ventricular-subgaleal shunt, endoscopic third ventriculostomy, and endoscopic
coagulation of the choroid plexus (Tully and Dobyns 2014). A non-invasive, therapeutic
approach towards ameliorating PHH would significantly improve long-term quality of
life for GMH patients.
PHH pathophysiology after GMH remains vague and complex, and minimal
advancements have been made in its clinical management. In this review, we discuss CSF
flow dynamics, particularly focusing on its importance in GMH. We highlight
advancements made in hydrocephalus research after Dr. Dandy first proposed the bulk
flow theory over a century ago. We discuss the current hydrodynamic theory for
hydrocephalus pathophysiology and how it applies to PHH development after GMH.
Special attention is given to the neurovascular unit in both the choroidal and glymphatic
microcirculation, where CSF is produced and reabsorbed, respectively. We identify gaps
in current research and propose avenues for further exploration.
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Cerebrospinal Fluid Flow Dynamics
Cerebrospinal fluid (CSF) is an isotonic solution that primarily acts as a
mechanical cushion for the brain, although it serves many other physiologically vital
functions as well (Chakravarthi 2012). CSF has a lower specific gravity than brain tissue,
creating a buoyant force that reduces the effective mass of the brain. CSF [H+]
concentration is detected by central chemoreceptors located at the ventrolateral medullary
surface, which help regulate pulmonary ventilation and cerebral blood flow to ensure the
brain receives ample oxygen and nutrients. CSF also maintains a stable external
environment for growth and development of neurons and glia (Chakravarthi 2012).
Importantly, CSF serves as a cerebral lymphatic conduit utilized for removing metabolic
waste and transporting neuropeptides, glucose, and lipids (Iliff, Wang et al. 2012; Xie,
Kang et al. 2013).

Production
Between 400-600 mL of CSF is produced per day and the brain renews its CSF
between 3-4 times within a 24 hour period (Pierce, Lambertsen et al. 1962; Cutler, Page
et al. 1968; Sahar 1972; Sato, Bering et al. 1975). CSF is primarily produced by the
ependymal lining of the ventricles, which compose the blood-CSF barrier. Ependymal
cells of the blood-CSF barrier are interconnected by tight junctions that are variably
distributed and leakier than ependymal cells of the blood-brain barrier. Over two thirds of
produced CSF originates from the choroid plexus (Pollay 1975; Segal and Pollay 1977).
The choroid plexus lines the lateral ventricles from the inferior horns to the
interventricular foramen, where it becomes continuous into the third ventricle and
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continues into the fourth ventricle. The choroid epithelium protrudes into the ventricles
through invaginations of the pia matter containing choroidal capillaries, called tela
choroidea, which significantly increase the surface area of the choroidal epithelium
(Davson and Segal 1970; Keep and Jones 1990; Speake and Brown 2004; Johanson,
Stopa et al. 2011). Non-choroidal ependymal cells, brain interstitial fluid, and capillaries
may be other CSF sources as well, which is secreted by transependymal seepage into the
brain ventricles or transpinal seepage into the subarachnoid space (Pollay and Curl 1967;
Davis and Milhorat 1975; Milhorat, Davis et al. 1975; Saunders, Habgood et al. 1999).
The posterior choroidal, anterior choroidal, inferior cerebellar and superior
cerebellar arteries supply the choroid plexus of the lateral ventricles, third ventricle,
fourth ventricle, and temporal horns, respectively (Milhorat 1978; Sakka, Coll et al. 2011;
Chakravarthi 2012). Blood flow to the choroidal epithelium is estimated at 4 - 6 mL /
minute / gram tissue, which is significantly greater than blood flow to other brain tissue
estimated at 0.9 - 1.8 mL / minute / gram tissue (Maktabi, Heistad et al. 1991). The
choroidal interstitial compartment is the region between choroidal capillaries and
choroidal ependymal cells. Choroidal capillaries lack tight junction proteins in their
endothelial cells, making them more permeable, and blood plasma filtrate passively
crosses into the choroidal interstitial compartment from the choroidal capillaries
primarily by Starling forces (Wright 1972; Welch 1975). Thus the main source for
produced CSF is technically choroidal capillaries, not the choroid plexus itself
(Oreskovic and Klarica 2010; Bulat and Klarica 2011; Oreskovic and Klarica 2011).
[Na+] and [Cl-] from choroidal interstitium are actively exchanged for [H+] and [HCO3-],
generated by cytosolic carbonic anhydrase on choroidal ependymal cells, using carrier
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proteins in the choroidal ependymal basolateral membrane. Pumps on the choroidal
ependymal apical membrane then expel [Na+], [Cl-], [K+], and [HCO3-] into the ventricle
lumen, which generates an osmotic pressure (Pollay 1975; Spector and Johanson 1989;
Keep and Jones 1990). Water flows down the created osmotic gradient with the help of
aquaporin 1 on the choroidal ependymal apical membrane (Reiber 2003). The CSF
contains higher concentrations of [Na+], [Mg2+], and [Cl-] than blood plasma but less
[Ca2+], [K+], [HCO3-], [PO4+], protein (contains 0.3% plasma proteins), amino acids, and
glucose (Felgenhauer 1974).
The choroidal epithelium can alter CSF secretion in response to multiple factors
and mechanisms. Most regulatory mechanisms target membrane transporters, carbonic
anhydrase, and aquaporins (Faraci, Mayhan et al. 1990; Sakka, Coll et al. 2011). The
NaK2Cl cotransporter, located on the choroidal ependymal apical membrane, helps
regulate CSF composition and secretion by its bi-directional transport ability. Arginine
vasopressin, atrial natriuretic peptide, serotonin, melatonin, and dopamine receptors are
located on choroidal epithelium. Arginine vasopressin and atrial natriuretic peptide
decrease CSF secretion. CSF secretion can also be increased by sympathetic innervation
and decreased by cholinergic innervation (Chakravarthi 2012). Pharmaceutical drugs that
inhibit carbonic anhydrase or sodium transporters, such as diuretics, reduce CSF
production, while drugs that augment cerebral blood flow tend to increase CSF
production. Increased intracranial pressure also tends to decrease CSF production,
although evidence suggests CSF production tends to remain constant despite large
increases in hydrostatic pressure (Sakka, Coll et al. 2011).
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Circulation
CSF flows from the sites of secretion at the choroidal epithelium to the sites of
absorption in the subarachnoid space. The mean CSF volume within the brain is 150 mL,
with 25 mL in the ventricles and 125 mL in the subarachnoid space (Sakka, Coll et al.
2011). Generally, CSF flows from the lateral ventricles, passes through the
interventricular foramen of Monro into the third ventricle, and finally passes into the
cerebral aqueduct of Sylvius into the fourth ventricle. From the fourth ventricle, CSF
enters through three openings, the lateral apertures of Lushka and median aperture of
Magendie, into the subarachnoid space where it is absorbed. A portion of the CSF exits
the cranium through arachnoid villi and cranial nerves while the remainder enters along
the spinal cord and exit through spinal nerve roots (Dichiro 1964; Milhorat 1976;
Chakravarthi 2012).
CSF circulates through the brain’s ventricular system and spinal cord in a
pulsatile manner. Cerebral arterial pulse waves are the primary drivers of CSF
circulation, although jugular venous pressure, respiratory waves, and even physical
activity play minor roles as well (Post, Allen et al. 1974; Williams 1976). CSF flow,
however, is very slow and sometimes occurs bi-directionally through ventricle
compartments with each cardiac and/or respiratory cycle, but net CSF flow occurs from
the lateral ventricles to the subarachnoid space. Additionally, ventricular ependymal cells
have cilia that generate current and propel CSF through the brain ventricles. CSF
pressure gradients, which are generated by continuous CSF secretion and arterial
pulsations, are also important for maintaining CSF flow. This pressure gradient is
particularly important in driving CSF flow through the subarachnoid spaces and venous
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sinuses. Indeed, CSF flow across the subarachnoid epithelium is driven by a 6 cm H2O
pressure difference between subarachnoid CSF pressure (approximately 15 cm H2O) and
superior sagittal sinus pressure (approximately 9 cm H2O), and the pressure continues to
drop into the jugular vein and systemic venous system (Shulman, Yarnell et al. 1964;
Bradley 1970; Sahar, Hochwald et al. 1970; Milhorat 1975).

Reabsorption
Conventionally CSF is reabsorbed in the subarachnoid space and enters through
the dural venous sinuses, where it returns to the internal jugular system (Chakravarthi
2012). Subarachnoid villi, called pacchonian bodies, were originally thought to be the
main reabsorption sites (Brierley and Field 1948; Welch and Friedman 1960; Welch
1975), but evidence suggests CSF is mainly reabsorbed by capillaries and cerebral
lymphatic channels (Bradbury, Cserr et al. 1981; Zakharov, Papaiconomou et al. 2003;
Oreskovic and Klarica 2010; Bulat and Klarica 2011; Oreskovic and Klarica 2011). The
vast majority of CSF is reabsorbed at the superior sagittal sinus with the remainder
reabsorbed at dural sinusoids in dorsal root nerves. Reabsorption is driven by pressure
gradients between the subarachnoid space and venous sinuses as well as Starling forces at
the capillaries (Cutler, Page et al. 1968; Zlokovic, Segal et al. 1990; Saunders, Habgood
et al. 1999; Pollay 2010). Increased intracranial pressure tends to increase CSF
reabsorption, but very high intracranial pressure that persists for a long period of time
tends to actually decrease CSF reabsorption, mostly because venous pressure tends to
increase with intracranial pressure while the overall pressure gradient diminishes. Some
evidence suggests CSF flows along cranial nerves and spinal nerve roots and is
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reabsorbed in lymphatic channels (Bradbury, Cserr et al. 1981; Zakharov, Papaiconomou
et al. 2003). Indeed, CSF reabsorption in the nasal submucosal lymphatic channels
through the cribriform plate, which feed into the cervical lymph nodes, is relatively
important (Courtice and Simmonds 1951; Erlich, McComb et al. 1986; Cserr, DePasquale
et al. 1992; Kida, Pantazis et al. 1993; Silver, Li et al. 1999; Mollanji, Bozanovic-Sosic et
al. 2002). Lymphatic vessels have also been recently characterized surrounding the dural
sinuses, which are also connected to cervical lymph nodes, further suggesting the
lymphatic system plays an important role in CSF reabsorption (Bradbury, Cserr et al.
1981; Zervas, Liszczak et al. 1982; Zakharov, Papaiconomou et al. 2003). Lymphaticmediated CSF reabsorption is thought to play a greater role in neonates, since
subarachnoid granulations are more sparsely distributed.
While the central nervous system lacks a conventional lymphatic system,
evidence suggests the presence of a functional waste clearance pathway involving
exchange between CSF and interstitial fluid, occurring mostly within perivascular
Virchow-Robin spaces in the brain parenchyma (Iliff, Wang et al. 2012; Iliff and
Nedergaard 2013; Jessen, Munk et al. 2015). This exchange system is called the
glymphatic system for its lymphatic-like function and dependence upon glial cells
(Figure 1.1). Cerebral arteries at the cortical surface extend into pial arteries running
through the subarachnoid space and subpial space, which turn into arterioles surrounded
by astrocyte end-feet as they run deeper into the brain parenchyma. The Virchow-Robin
space is the CSF containing perivascular space between the astrocyte end-feet and
arteriole, with both walls lined by a leptomeningeal cell layer (Zhang, Inman et al. 1990;
Kulik, Kusano et al. 2008; Zlokovic 2011; Prince and Ahn 2013). Virchow-Robin spaces
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along veins lack this leptomeningeal cell layer. Arteriole Virchow-Robin spaces become
continuous with the basal lamina, which has minimal resistance to CSF flow due to its
loosely structured extracellular matrix (ECM). CSF flows along arteriole Virchow-Robin
space, through basal lamina surrounding capillaries, and exits through the venous
Virchow-Robin space. Arterial pulsation is the main force driving perivascular fluid bulk
movement from the subarachnoid space into the Virchow-Robin spaces; although
respiration, slow vasomotion, and CSF pressure gradients play minor roles too (Iliff,
Wang et al. 2012; Iliff and Nedergaard 2013; Jessen, Munk et al. 2015). Astrocyte endfeet have high expression of aquaporin 4 and are important for CSF exchange with
interstitial fluid, since astrocyte end-feet surround perivascular spaces and drive
convective interstitial fluid fluxes from periarterial to perivenous spaces. Interstitial fluid
then drains into cervical lymph channels from perivenous spaces (Johnston, Zakharov et
al. 2004; Murtha, Yang et al. 2014).
The glymphatic system is particularly important for distributing nutrients, such as
glucose and lipids, as well as for removing soluble proteins and metabolites from the
brain (Rangroo Thrane, Thrane et al. 2013). Glymphatic-mediated exchange is greatest
during sleep, which is thought to be important for removing metabolic waste during the
resting state (Xie, Kang et al. 2013). In rodent models of Alzheimer’s disease,
glymphatic-mediated exchange was reduced by 65% in aquaporin 4 knockout mice,
resulting in increased accumulation of β-amyloid plaques (Iliff, Wang et al. 2012). In a
mouse repeated traumatic brain injury model, glymphatic exchange was reduced at 24
hours after the last injury and persisted for up to 4 weeks, which was attributed to gliosis
(Plog, Dashnaw et al. 2015). Furthermore, the glymphatic system was significantly
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impaired after subarachnoid hemorrhage, due to blood clots occluding perivascular
spaces, and during ischemic stroke, due to reduced arterial pulsations (Gaberel, Gakuba
et al. 2014). More research is further elucidating the pathophysiological role the
glymphatic system plays in multiple neurodegenerative diseases and injuries, and this
system may be particularly important in neonatal GMH and consequent PHH
pathophysiology due to the role it plays in CSF dynamics.
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Figure 1.1: Overview of the glymphatic system. Cerebrospinal fluid enters within paraarterial Virchow-Robin spaces in the brain parenchyma and an astroglia-mediated
mechanism exchanges cerebrospinal fluid with interstitial fluid and flushes wastes out
within para-venous Virchow-Robin spaces (A). Astrogliosis (B) from brain injury
possibly disrupts this astroglia-dependent mechanism.
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Hydrocephalus
The International Hydrocephalus Imaging Working Group defines hydrocephalus
as “an active distension of the ventricular system resulting from inadequate passage of
cerebrospinal fluid from its point of production within the cerebral ventricles to its point
of absorption into the systemic circulation” (Rekate 2008). Clinical consequences can
include increased intracranial pressure, seizures, mental deterioration, and tunnel vision.
Most treatments involve surgical implantation of shunts that divert CSF from the brain or
surgery, if possible, to repair any malformations that contribute towards hydrocephalus
development (Kahle, Kulkarni et al. 2015). Dr. Dandy and Dr. Blackfan classified
hydrocephalus into communicating and non-communicating hydrocephalus in 1914 after
inducing hydrocephalus in dogs by obstructing the foramen of Monro (Dandy 1914).
They proposed the bulk flow theory, which states that CSF flows in bulk from the sites of
production in the ventricles to the sites of reabsorption in the subarachnoid space.
Hydrocephalus, according to bulk flow theory, had to result from an imbalance in CSF
production and absorption. Using the same conceptual framework, Dr. Russell proposed a
more specific classification of hydrocephalus in 1949 into non-obstructive and
obstructive hydrocephalus, which corresponds to communicating and noncommunicating hydrocephalus, respectively (Russell 1949). The original terms proposed
by Dr. Dandy, however, remain the most pervasively utilized. Advancements involving
CSF tracers and imaging technology, however, has produced evidence challenging the
bulk flow theory (Symss and Oi 2013). New hydrocephalus classifications have been
proposed based on more recent experimental and clinical evidence, which will be
discussed.
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Non-communicating Hydrocephalus
Hydrocephalus resulting from an obstruction of CSF flow through ventricular and
subarachnoid spaces is called non-communicating hydrocephalus, also known as
obstructive hydrocephalus (McAllister 2012; Kahle, Kulkarni et al. 2015). Noncommunicating hydrocephalus is typically caused by congenital cerebral malformations.
Arnold-Chiari malformation, which is the displacement of the cerebellar tonsils through
the foramen magnum, often obstructs the fourth ventricle, leading to dilation of the lateral
ventricles and cerebral aqueduct (Gardner 1965). Dandy-Walker malformations,
characterized by the absence of the cerebellar vermis, often obstruct the foramina of
Luschka and foramen of Magendie, resulting in prominent dilation of the fourth ventricle
(Hirsch, Pierre-Kahn et al. 1984). Colloid cysts may obstruct the Foramen of Monro,
resulting in lateral ventricular dilation (Camacho, Abernathey et al. 1989). Other lesions
may cause abhorrent narrowing of the aqueduct of Sylvius, called aqueductal stenosis,
resulting in third and lateral ventricular dilation.

Communicating Hydrocephalus
Communicating hydrocephalus is impaired CSF reabsorption in the absence of
any obstruction to CSF flow through the ventricles and subarachnoid spaces (McAllister
2012; Kahle, Kulkarni et al. 2015). Communicating hydrocephalus was believed to
primarily result from impaired arachnoid granulations, resulting in reduced reabsorption
of CSF. Indeed, cerebral malformations resulting in the absence of arachnoid villi has
resulted in hydrocephalus development (Gutierrez, Friede et al. 1975). Subarachnoid
hemorrhage and intraventricular hemorrhage, which induce inflammation and glial
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scarring in the subarachnoid space, can cause communicating hydrocephalus as well
(Korobkin 1975; Vassilouthis and Richardson 1979). Accumulating evidence, however,
challenges the presumption that CSF is mostly absorbed by subarachnoid villi (Greitz
2004; Oreskovic and Klarica 2011). Normal pressure hydrocephalus is a form of
communicating hydrocephalus that results in ventriculomegaly without increased CSF
pressure. CSF pressure readings are within normal range because ventricular dilation
compensates for accumulated CSF in the ventricles, thus increased CSF pressure is
compensated by increased ventricular volume in this pressure-volume compensatory
relationship (Black and Ingraham 2008). In general, the elderly population is most
vulnerable to normal pressure hydrocephalus, and causes are either idiopathic or related
to other central nervous system diseases and injuries, particularly subarachnoid
hemorrhaging. Hydrocephalus ex vacuo is different from normal pressure hydrocephalus
because ventricular dilation results from brain tissue atrophy, usually due to a
neurodegenerative disorder, and not as a compensatory mechanism for increased CSF
pressure (Rekate 2009). Normal pressure hydrocephalus, however, contradicts bulk flow
theory, because the ventricles should not dilate without increased mean CSF pressure.

Current Hydrodynamic Theory
Although bulk flow theory is congruent with non-communicating hydrocephalus
development, when a ventricular obstruction creates back pressure that dilates the
ventricles preceding the obstruction, it is incongruent with communicating
hydrocephalus, because the apparent obstruction is within the subarachnoid space, which
does not dilate or increase in volume (Greitz 2004; Oreskovic and Klarica 2011). In 1914,
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Dr. Weed injected Prussian blue into the ventricles of dog and cat brains and found the
dye accumulated near pacchonian bodies (Weed 1914). Prussian blue, however, was also
found in other brain parenchymal areas, and further research concluded Prussian blue
cannot cross pacchonian bodies under normal conditions (Symss and Oi 2013). Even Dr.
Dandy recognized reduced bulk flow across pacchonian bodies should result in
subarachnoid CSF pressure being greater than ventricular CSF pressure and the
subarachnoid space should expand before the ventricles, neither of which is observed. Dr.
Dandy concluded CSF is primarily reabsorbed in the subarachnoid space and quickly
enters the circulatory system, based on intrathecal dye injections that rapidly entered the
blood and urine (Dandy 1929). The idea that CSF is mostly reabsorbed at pacchonian
bodies, however, remained pervasive. In 1960, Dr. Welch reported pacchionian bodies
could act as mechanical valves, although future anatomical studies found no mechanical
valve presence (Welch and Friedman 1960). Dr. Di Chiro started experimenting with
radionuclide cisternography and, in 1966, suggested CSF was reabsorbed at pacchionian
bodies because radionuclide accumulated there after 24 hours (Di Chiro 1966). Future
studies, however, challenged this conclusion since other radionuclides enter the
circulatory system within minutes and most are reabsorbed in the spinal canal (Greitz
1993; Greitz and Hannerz 1996; Greitz, Greitz et al. 1997). Furthermore, sites where
radionuclides accumulate after a long period of time may indicate sites where CSF
reabsorption is actually very limited. A radionuclide cisternography study in patients with
venous vasculitis and high intracranial pressure, performed by Dr. Greitz and Dr.
Hannerz in 1996, found no tracer in vessel outlets near capillary beds of pacchonnian
bodies, providing evidence for an alternative site of CSF reabsorption (Greitz and
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Hannerz 1996). Another major issue is pacchonian bodies are absent in infants and young
children, suggesting CSF must be reabsorbed by a different mechanism (Papaiconomou,
Bozanovic-Sosic et al. 2002).
Some scientists investigated if abnormal vascular and CSF pulsations may be the
root cause for communicating hydrocephalus. In 1943, after observing normal pressure
hydrocephalus patients and noting inconsistencies with the bulk flow theory, Dr.
O’Connell proposed communicating hydrocephalus may result from increased ventricular
pulse pressure (O’Connell 1943). Dr. Bering provided experimental evidence in 1962 that
choroid plexus pulsations deliver the means for ventricular enlargement instead of
increased mean CSF pressure (Bering 1962). Dr. Bering used a kaolin-induced
hydrocephalic dog model and excised the choroid plexus from one lateral ventricle,
which resulted in asymmetric ventricular dilation. Increased mean CSF pressure,
therefore, could not account for asymmetric ventricular dilation. Dr. Di Rocci provided
additional experimental evidence in 1978 in which extreme ventricular pulsation, caused
by inflating and deflating a microballon inserted into the lateral ventricles, can produce
hydrocephalic ventricular dilation in sheep (Di Rocco, Pettorossi et al. 1978).
Concurrently, Dr. Guinane in 1977 produced olfactory ventricular dilation, which lacks a
choroid plexus, in rabbits by obstructing surrounding subarachnoid spaces with silicone
rubber (Guinane 1977). The silicone rubber obstruction decreased subarachnoid arterial
and venous compliance as well as increased capillary pulsations. Increased capillary
pulsations, therefore, had to generate the force necessary for the observed ventricular
dilation. Using magnetic resonance imaging and radionuclide cisternography, Dr. Greitz
reported in the early to mid-1990s arterial pulsation and expansion provides the force
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necessary for CSF pulsatile circulation in both the brain and spinal cord, and arterial
compliance is important for keeping capillary and venous pulsation low (Greitz 1993;
Greitz and Hannerz 1996; Greitz, Greitz et al. 1997; Greitz 2004).
According to bulk flow theory in which CSF malabsorption is a causative factor
for communicating hydrocephalus, the subarachnoid CSF-venous pressure gradient
would increase, the subarachnoid space would expand, and the ventricles would dilate
after subarachnoid space compliance is at maximum. In actuality, the subarachnoid space
is smaller, and the subarachnoid CSF-venous pressure gradient is diminished, although
both the subarachnoid CSF pressure and venous pressure increase. In 2002, Dr. Egnor
developed a mathematical model of communicating hydrocephalus caused by a
redistribution of CSF pulsations in the brain (Egnor, Zheng et al. 2002). Decreased
intracranial compliance causes abnormal distribution of vascular pulsations, such that
arterial pulsations are weaker while capillary and venous pulsations are stronger, and
stronger pulsations reach the ventricles while weaker pulsations reach the subarachnoid
space. Thus, this vascular pulsation redistribution causes the ventricles to expand at the
expense of the subarachnoid space and decreases the subarachnoid CSF-venous pressure
gradient. Dr. Edgor’s model, based on alternating current electric circuitry, accounted for
experimentally and clinically observed CSF malabsorption, increased resistive index,
ventricular dilation, intracranial pressure waves, reduced cerebral blood flow, and
diminished CSF-venous pressure gradient. Dr. Greitz elaborated on this concept in 2004
in his discussion of hydrodynamic theory of chronic hydrocephalus development.
Reduced intracranial compliance causes decreased arterial pulsations and increased
compensatory capillary pulsations, generating transmantle pulsatile stress responsible for
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hydrocephalus. CSF malabsorption, therefore, is not a causative factor of communicating
hydrocephalus but an effect from vascular pulsatile redistribution (Greitz 2004). Dr.
Oreskovic further suggests that disruption of Starling forces in the brain parenchymal
microvasculature lead to an imbalance in interstitial fluid and CSF exchange, contributing
to hydrocephalus development (Oreskovic and Klarica 2011).
In light of our increased understanding of hydrocephalus pathophysiology, Dr. Oi
and Dr. Di Rocco proposed a new classification based on the involved pathway: major
pathway hydrocephalus and minor pathway hydrocephalus (Oi and Di Rocco 2006).
Major pathway hydrocephalus accounts for CSF circulation disruption from the ventricles
to the subarachnoid spaces. Major pathway hydrocephalus encompasses most obstructive
/ non-communicating hydrocephalus cases. Minor pathway hydrocephalus accounts for
disruptions in CSF circulation within the subarachnoid space and brain parenchyma.
Evidence suggests this pathway is very important for CSF reabsorption in the embryo,
fetus, and infants, making it critical for infantile hydrocephalus development
(Papaiconomou, Bozanovic-Sosic et al. 2002). Minor pathway hydrocephalus is
disruption of CSF flow and reabsorption in newly elucidated channels in the brain
parenchyma, which involve deep vascular structures and lymphatic channels (Figure 1.2).
Dr. Nedergaard further characterized this pathway in rodents using in vivo two photon
imaging and coined the term “glymphatic system”, since this functional waste clearance
pathway involves astroglia and lymphatic-like paravascular channels (Iliff, Wang et al.
2012). CSF enters from the subarachnoid space into paravascular artery channels and
exchanges with interstitial fluid, which is cleared through paravascular veins. Additional
lymphatic channels lining the dural sinuses and meningeal arteries were characterized by
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Dr. Louveaue and Dr. Aspelund (Aspelund, Antila et al. 2015; Louveau, Smirnov et al.
2015). These lymphatic vessels connect the meningeal compartment with the glymphatic
system. As the cerebral glymphatic / lymphatic systems are further characterized, more
research is warranted on their potential pathophysiological roles played in hydrocephalus
development.
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Figure 1.2: Paravascular Virchow-Robin spaces depicted on MRI. Axial noncontrasted brain MRI demonstrating perivascular spaces (arrows) that appear hypointense
to brain tissue and isointense to CSF in T1-weighted (A) and T2-weighted (B) sequences.

23

Post-hemorrhagic Hydrocephalus Pathophysiology and Potential Mechanisms
PHH is a common debilitating consequence of severe grade GMH, and the
mechanisms contributing to PHH development remain to be elucidated.
Cerebroventricular expansion leads to mechanical compression of surrounding brain
tissue, causing injury and consequent neurological deficits in patients surviving the initial
bleed (Robinson 2012). PHH was commonly theorized to be caused by blood clots
obstructing the cerebral aqueduct or formanina of Luschka and Magendie or by
microthrombi obstructing small CSF outflow passages in the subarachnoid space. Much
evidence suggests a variety of inter-related pathophysiological mechanisms that
potentially alter normal CSF dynamics play significant roles in PHH development as well
(Strahle, Garton et al. 2012; Whitelaw and Aquilina 2012; Tang, Tao et al. 2016).
Applying concepts in current hydrocephalus theory towards PHH development after
GMH may better illuminate potential mechanisms for therapeutic intervention (Figure
1.3).

Blood Clots, Hemoglobin, and Iron
Non-communicating / obstructive PHH may result from cerebroventricular blood
clots and microthrombi directly impairing CSF circulation and absorption by obstructing
the cerebral aqueduct, formanina of Luschka and Magendia, and subarachnoid CSF
outflow passages. Subsequently, it was hypothesized intraventricular fibrinolytic therapy
would remove cerebroventricular blood clots and reduce PHH incidence (Whitelaw and
Aquilina 2012). In an adult intraventricular hemorrhage dog model, in which
intraventricular blood injection resulted in 80% of dogs developing PHH, intraventricular
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urokinase injection reduced PHH incidence to 10% (Pang, Sclabassi et al. 1986). Clinical
investigations of intraventricular streptokinase, urokinase, or tissue plasminogen activator
injections after GMH, however, concluded fibrinolytic therapy did not improve long-term
dependence on ventriculo-peritoneal shunts (Whitelaw 1993). Thus, cerebroventricular
obstruction from thrombi may play only a minor role in long-term PHH development.
Although intraventricular fibrinolytic therapy failed to improve clinical PHH
outcomes, evidence suggests hemoglobin and iron may play an important role in PHH
development (Strahle, Garton et al. 2014). Erythrocyte lysis after hemorrhage, typically
from complement activation and consequent membrane attack complex formation,
releases hemoglobin and iron into surrounding brain tissue. Experimental adult cerebral
hemorrhage models conclude hemoglobin metabolites and iron contributes towards brain
edema (Chen, Gao et al. 2011). Hemoglobin metabolites were also found in the CSF of
rabbit pups with intraventricular hemorrhage, and iron was elevated in the CSF of
preterm infants with PHH (Savman, Nilsson et al. 2001; Lee, Keep et al. 2010).
Intraventricular injection of hemoglobin or iron into neonatal rat pups also resulted in
significant acute ventricular dilation (Strahle, Garton et al. 2014). Additionally, acute and
delayed iron chelation by Deferoxamine reduced long-term PHH development in
neonatal rats after GMH (Klebe, Krafft et al. 2014). Iron, thus, is a quintessential player
in PHH formation, although the exact mechanisms remain unclear.
Gene deletion studies determined iron transport and iron-dependent metabolic
proteins are highly expressed in the ependymal lining compared to other brain tissue
(Keep and Smith 2011). Thus, the ependymal lining may be adversely affected from iron
overload due to GMH. Indeed, ependymal cells are theorized to prevent iron diffusion
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into the brain parenchyma by up-taking it from the CSF (Moos 2002). Additionally, iron
overload has been associated with increased expression of aquaporin 4 in adult rats with
cerebral hemorrhage, and Deferoxamine treatment reduced aquaporin 4 expression (Qing,
Dong et al. 2009). Iron, thus, may regulate expression of ependymal ion and water
channels, such as aquaporin 4, and contribute towards PHH by altering CSF production
dynamics at the ependymal layer. It should be noted, however, that diuretic treatments
targeting ependymal channels were evaluated in clinical trials of preterm GMH patients
and determined to have no clinical benefit. More research is needed to further elucidate
iron’s pathophysiological role in development of hydrocephalus.

Inflammation, Fibrosis, and Gliosis
Inflammation has been associated with subependymal gliosis, fibrosing
arachnoiditis, and meningeal fibrosis after GMH (Cherian, Whitelaw et al. 2004; Oi and
Di Rocco 2006). GMH patients also have increased expression levels of inflammatory
markers in their CSF, including TNF-α (Savman, Blennow et al. 2002). Vessel rupture
results in blood and serum components entering the brain parenchyma. Resident immune
cells, namely microglia, are activated by stimulating toll-like receptors and nod-like
receptors with damage-associated molecular patterns, molecules that induce a noninfectious inflammatory response (Klebe, McBride et al. 2015). Activated microglia
secrete pro-inflammatory cytokines, extracellular proteases, and oxidative species, which
damage surrounding tissue and recruit leukocytes that exacerbate inflammation (Chen,
Yang et al. 2015; Yang, Salayandia et al. 2015). In neonatal rat pups with GMH,
microglia proliferation was observed in the perihematoma region, microglia activation

26

was associated with phosphorylated ERK, and modulating microglia activation with
minocycline or cannabinoid receptor 2 agonist ameliorate inflammation and improved
outcomes (Tang, Chen et al. 2015; Tang, Tao et al. 2015). Interestingly, microglia may
play an important role in hematoma resolution, since stimulating PPARγ improved shortterm hematoma resolution, which was dependent upon CD36 scavenger receptor and was
associated with inducing the alternatively activated M2 microglia/macrophage phenotype
(Flores, Klebe et al. 2016).
Fibrosis is the forming of excess connective tissue as a consequence of a
reparative process after inflammation (Birbrair, Zhang et al. 2014). Excess fibrous tissue
formation may disrupt the normal functioning of surrounding tissue. Multiple factors
trigger fibrosis after GMH. Thrombin, which is significantly active up to 10 days after
GMH in neonatal rats, cleaves fibrinogen into fibrin to form fibrin clots, activates the
complement pathway to augment inflammation, and stimulates protease-activated
receptors (PARs), a family of G protein-coupled receptors (Luo, Wang et al. 2007; Babu,
Bagley et al. 2012; Lekic, Klebe et al. 2015). PAR stimulation has been associated with
fibrosis in several tissues, including liver, renal, pulmonary, and cardiac tissues. PAR
stimulation upregulates mammalian target of rapamycin (mTOR), which is associated
with ECM protein proliferation. Additionally, PAR stimulation exacerbates inflammation
by upregulating cyclo-oxygenase 1 and 2 activity (Kataoka, Hamilton et al. 2003;
Steinhoff, Buddenkotte et al. 2005; Luo, Wang et al. 2007). Phosphorylated mTOR and
cyclo-oxygenase 2 levels were increased by 72 hours after GMH in rats, which were both
reduced by combinatorial PAR-1,4 inhibitor administration (Lekic, Klebe et al. 2015).
ECM proteins are theorized to deposit within the cerebroventricular system, similar to
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blood clots and microthrombi (Strahle, Garton et al. 2012; Bowen, Jenkins et al. 2013;
Tang, Tao et al. 2016). ECM protein overproduction, therefore, may obstruct normal CSF
flow pathways. Indeed, fibronectin and vitronectin expression levels are significantly
increased in GMH rats with long-term PHH (Klebe, Krafft et al. 2014; Manaenko, Lekic
et al. 2014). Inhibiting mTOR with rapamycin and inhibiting cyclo-oxygenase 2 activity
ameliorated long-term PHH and neurocognitive deficits in GMH rats, although
expression levels of ECM proteins was not determined in this study (Lekic, Klebe et al.
2015).
TGF-β stimulates mesenchymal stem cells and fibroblasts, which produce ECM
matrix proteins and deposit connective tissue (Bowen, Jenkins et al. 2013). TGF-β can be
secreted from activated microglia, and TGF-β secretion can be induced by thrombin
(Schuliga 2015). ECM production induced by TGF-β stimulation may deposit in the
cerebroventricular system, disrupting CSF dynamics (Tada, Kanaji et al. 1994). A rabbit
pup GMH model indicated TGF-β, fibronectin, and laminin expression levels were
significantly increased in the ependymal and subependyma tissue after GMH (Cherian,
Thoresen et al. 2004). Mice with transgenic TGF-β overexpression developed
hydrocephalus with higher expression of ECM proteins in the brain than wild-types
(Wyss-Coray, Feng et al. 1995). In a clinical study, increased TGF-β1 and ECM protein
expression in the CSF were associated with PHH development in preterm infants
(Aquilina, Chakkarapani et al. 2012; Douglas-Escobar and Weiss 2012). The TGF-β1
isoform is most associated with PHH after IVH in neonates and adults (Gomes, Sousa
Vde et al. 2005). Intrathecal TGF-β1 injection in mice resulted in hydrocephalus
development, and TGF-β1 expression was significantly increased in brains of neonatal

28

rats with PHVD after intraventricular blood injection (Tada, Kanaji et al. 1994; Cherian,
Thoresen et al. 2004). Indeed, TGF-β1 was elevated in both animal models and premature
infants with PHH, although some studies dispute this (Heep, Stoffel-Wagner et al. 2004).
In a rat GMH model, TGF-β1 was elevated within hours after GMH, but normalized by
24 hours post-ictus (Tang, Chen et al. 2015). Additionally, inhibiting TGF-β1
ameliorated long-term PHH and neurocognitive deficits as well as reduced vitronectin
and GFAP expression in rats (Manaenko, Lekic et al. 2014). Although the mechanism of
TGF-β signaling after GMH and its association with PHH development has been
established, studies are lacking that discern the changes to CSF dynamics as a
consequence of TGF-β signaling and fibrosis.
Gliosis results from damage to the central nervous system and is characterized by
the nonspecific reactive proliferation of astrocytes, microglia, and oligodendrocytes
(Sofroniew 2009). Hydrocephalus development is also associated with
neuroinflammation and reactive gliosis (Del Bigio, Wilson et al. 2003; Deren, Forsyth et
al. 2009). Gliosis was observed in cerebral cortical biopsies from hydrocephalic children
with shunts (Glees and Hasan 1990). Increased expression of Iba-1 and GFAP, markers
for microglia and astrocytes respectively, were also observed in the brains of neonatal
rats with hydrocephalus (Deren, Packer et al. 2010). Reactive gliosis in the subarachnoid
space was associated with hydrocephalus development after subarachnoid hemorrhage in
rats. In an IVH rat model, long-term GFAP expression is markedly increased, and
injection of umbilical cord blood-derived mesenchymal stem cells reduced GFAP
expression as well as long-term PHH development (Ahn, Chang et al. 2013). Aquaporin 4
knockout mice more rapidly developed hydrocephalus after kaolin injection, although
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increased aquaporin 4 expression is observed in hydrocephalus too (Bloch, Auguste et al.
2006; Mao, Enno et al. 2006). Aquaporin 1 is expressed on the choroid plexus apical
membrane and aquaporin 1 knockout mice had decreased CSF production (Oshio,
Watanabe et al. 2005). Given the important role astrocytes play in the blood-brain and
blood-CSF barrier functions as well as in glymphatic mediated CSF-interstitial fluid
exchange, gliosis may have a profound effect on CSF dynamics and PHH development,
which warrants further investigation.
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Figure 1.3: Summary of GMH Pathophysiological Pathways. Know pathways and
potential mechanisms disrupting cerebrospinal fluid dynamics and contributing to posthemorrhagic hydrocephalus development after germinal matrix hemorrhage.
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Conclusions
Our understanding of hydrocephalus has changed significantly since Dr. Dandy’s
first experiments in the early 20th century and the bulk flow theory was proposal. The
source for CSF production is choroidal and ependymal capillaries, and the source for CSF
reabsorption are subarachnoid and parenchymal capillaries as well as perivascular
channels following glymphatic mediated CSF-interstitial fluid exchange. The current
hydrodynamic theory suggests hydrocephalus develops from disruptions in hydrostatic
and osmotic pressures in the brain microvasculature as well as disruptions in vascular
pulsatile distribution due to alterations in overall brain compliance. Our purpose is to
reconcile our knowledge of GMH and PHH development with the current hydrodynamic
theory of hydrocephalus. Indeed, many GMH/IVH studies suggest PHH is a consequence
of obstructions within the cerebroventricular system and subarachnoid drainage pathways
due to thrombi, gliosis, and fibrosis. In line with current hydrocephalus school of thought,
we suggest thrombi, gliosis, and fibrosis after GMH are not merely obstructing CSF
passages but are altering barrier dynamics in the microvasculature and ependymal lining,
altering CSF dynamics and CSF-interstitial fluid exchange to cause PHH development.
Future research should elucidate these potential mechanisms.

Specific Aims
Post-hemorrhagic hydrocephalus is a debilitating consequence of germinal matrix
hemorrhage (Ballabh 2010; Heron, Sutton et al. 2010). Thrombin as well as
intracerebroventricular blood clots have been identified as causative factors of
hydrocephalus formation. Thrombin initiates inflammatory responses, gliosis, and
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overproduction of ECM proteins that may permanently obstruct the cerebroventricular
system (Xue, Balasubramaniam et al. 2003; Cherian, Whitelaw et al. 2004; Volpe 2009).
Thrombin mediates brain injury by activating PARs (Kataoka, Hamilton et al. 2003;
Steinhoff, Buddenkotte et al. 2005). PAR stimulation leads to phosphorylation and
subsequent activation of mTOR, which is linked to overproduction of ECM proteins that
cause impaired CSF circulation and absorption (Paul, Leef et al. 2000; Crews, WyssCoray et al. 2004; Del Bigio 2004; Xue and Del Bigio 2005; Ballabh, Xu et al. 2007;
Dummula, Vinukonda et al. 2010). Blood clots directly impair CSF circulation and
absorption. Previous studies of adult hemorrhagic stroke suggest activation of PPARγ
enhances microglial phagocytosis of red blood cells via CD36 scavenger receptor, which
results in enhanced clot resolution and improved neurobehavioral outcomes (Zhao, Zhang
et al. 2006; Zhao, Sun et al. 2007). Additionally, lysed red blood cells and metabolized
hemoglobin releases non-protein bound iron, which mediates brain injury and is
associated with PHH development. The objective of this proposal is to characterize the
extent of GMH-induced brain injury and evaluate the implications of thrombin, PARs,
PPARγ, CD36, and iron in GMH pathophysiology. The long-term goals are to provide
non-invasive, therapeutic approaches for GMH patients. The central hypothesis is the
inhibition of thrombin or thrombin’s downstream effectors PAR-1 and mTOR as well as
enhancement of clot and iron clearance via PPARγ and iron chelation respectively
reduces GMH-induced hydrocephalus and improves long-term neurological function in
rats. The hypothesis will be tested in two specific aims.
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Aim 1
Determine the role of PPARγ in clot clearance as well as iron chelation by
Deferoxamine after GMH. PPARγ activation will enhance CD36-mediated microglial
phagocytosis of red blood cells and, thus, reduce blood clots and subsequent
hydrocephalus after GMH. Iron chelation will also improve long-term neurological and
brain morphological outcomes after GMH. Aim 1A will investigate the time-course of
PPARγ and CD36 expression as well as the time course of hematoma resolution after
PPARγ stimulation or inhibition after GMH. Long-term brain morphological and
neurological outcomes following PPARγ stimulation or inhibition will also be evaluated.
Short-term hematoma resolution from PPARγ stimulation will be reversed by CD36
knockdown. Aim 1B will investigate if acute or delayed iron chelation treatment will
improve long-term neurological and brain morphological outcomes as well as reduce
ECM protein proliferation after GMH.

Aim 2
Determine the role of activated thrombin/PAR-1/mTOR pathway in GMH
induced hydrocephalus. Thrombin activation and stimulation of its downstream receptor,
PAR-1, will lead to mTOR activation and consequent ECM overproduction after GMH,
resulting in long-term post-hemorrhagic hydrocephalus development and neurological
deficits. Aim 2A will investigate the time course of thrombin activation and if
combinatorial PAR-1 and PAR-4 inhibition will reduce short-term COX-2 and mTOR
activation as well as if COX-2 and mTOR inhibition will improve long-term
neurobehavioral and brain morphological outcomes. Aim 2B will investigate if direct

34

thrombin or PAR-1 inhibition will reduce short-term mTOR activation, improve
neurobehavioral and brain morphological outcomes, and reduce long-term ECM protein
proliferation. PAR-1 stimulation will attempt to reverse effects from PAR-1 inhibition.
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Figure 1.4: Schematic representation of the overall central hypothesis and research
aims. Our central hypothesis is thrombin/PAR-1/mTOR pathway inhibition, enhanced
PPARγ/CD36 mediated phagocytosis of blood clots, and iron chelation after germinal
matrix hemorrhage will ameliorate long-term post-hemorrhagic hydrocephalus and
consequent neurofunctional deficits. Aim 1 will investigate PPARγ/CD36 mediated
hematoma resolution by microglia/macrophage phagocytosis as well as iron chelation by
Deferoxamine. Aim 2 will investigate the thrombin/PAR-1/mTOR pathway and
extracellular matrix protein proliferation.
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Abstract
Germinal matrix hemorrhage remains the leading cause of morbidity and
mortality in preterm infants in the United States with little progress made in its clinical
management. Survivors are often afflicted with long-term neurological sequelae,
including cerebral palsy, mental retardation, hydrocephalus, and psychiatric disorders.
Blood clots disrupting normal cerebrospinal fluid circulation and absorption after
germinal matrix hemorrhage are thought to be important contributors towards posthemorrhagic hydrocephalus development. We evaluated if upregulating CD36 scavenger
receptor expression in microglia and macrophages through PPAR stimulation, which
was effective in experimental adult cerebral hemorrhage models and is being evaluated
clinically, will enhance hematoma resolution and ameliorate long-term brain sequelae
using a neonatal rat germinal matrix hemorrhage model. PPAR stimulation (15d-PGJ2)
increased short-term PPAR and CD36 expression levels as well as enhanced hematoma
resolution, which was reversed by a PPAR antagonist (GW9662) and CD36 siRNA.
PPAR stimulation (15d-PGJ2) also reduced long-term white matter loss and posthemorrhagic ventricular dilation as well as improved neurofunctional outcomes, which
were reversed by a PPAR antagonist (GW9662). PPAR-induced upregulation of CD36
in macrophages and microglia is, therefore, critical for enhancing hematoma resolution
and ameliorating long-term brain sequelae.
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Introduction
The ganglionic eminence consists of neuronal and glial precursor cells located at
the head of the caudate nucleus below the lateral ventricles of the developing fetus, and
the highly vascularized region within the subependymal tissue is the germinal matrix.
Cerebral blood flow fluctuation associated with hemodynamic and respiratory instability
in preterm infants in conjunction with the inherent fragility of the germinal matrix often
leads to germinal matrix hemorrhage, a very common and major neurological
complication of prematurity. Germinal Matrix Hemorrhage (GMH) occurs when
immature blood vessels rupture within the subependymal (or periventricular) germinal
region of the ganglionic eminence in the immature brain (Ballabh 2010). In the United
States alone, GMH occurs in approximately 12,000 lives births per year, and the number
of moderate-to-severe GMH cases has remained steady over the past two decades
(Fanaroff, Stoll et al. 2007; Jain, Kruse et al. 2009; Osterman, Kochanek et al. 2015).
Clinical studies indicate GMH afflicted infants often suffer from long-term neurological
deficits, cerebral palsy, mental retardation, hydrocephalus, and psychiatric disorders
(Kadri, Mawla et al. 2006; Ballabh 2014). Prenatal glucocorticoid treatment remains the
best treatment for preventing GMH, yet minimal advancements have been made in GMH
clinical management post-ictus (Shankaran, Bauer et al. 1995; Roberts and Dalziel 2006).
Hemodynamic and respiratory instability in preterm infants results in fluctuations
of cerebral blood flow in the inherently frail germinal matrix vasculature, often resulting
in spontaneous bleeding (Ballabh 2014). The consequent hematoma applies mechanical
pressure to glia and neurons, resulting in cytotoxicity and necrosis, as well as evokes an
inflammatory response, leading to secretion of destructive proteases and oxidative
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species (Lekic, Klebe et al. 2015). In adult cerebral hemorrhage, clinical studies indicate
hematoma volume is the best prognostic indicator; larger hematoma volumes have
worsened outcomes (Keep, Xi et al. 2005; Xi, Keep et al. 2006). Experimental adult
cerebral hemorrhage studies proved more rapid hematoma resolution is necessary for
quickly ameliorating inflammation and improving neurological recovery (Zhao, Sun et al.
2007; Zhao, Grotta et al. 2009). Additionally, blood clots directly impair cerebrospinal
fluid circulation and absorption after GMH, significantly contributing towards posthemorrhagic hydrocephalus development (Cherian, Whitelaw et al. 2004; Aquilina,
Chakkarapani et al. 2011). Therefore, we hypothesize enhancing hematoma resolution
will improve GMH outcomes.
Microglia are resident macrophages of the central nervous system and are critical
drivers of the neuro-inflammatory response after GMH and other hemorrhagic brain
injuries (Aronowski and Zhao 2011; Tang, Chen et al. 2015). Activated microglia recruit
hematogenous phagocytes to the injured site, which engulf the hematoma as well as
damaged or dead tissue (Cox, Crossley et al. 1995; Aronowski and Hall 2005). The role
microglia play in hemorrhagic brain injury pathogenesis is different in neonates than
adults (Woo, Wang et al. 2012). Unlike the adult brain where microglia cells and
macrophages contribute to brain injury after stroke through the production of
inflammatory cytokines (Vexler and Yenari 2009), neonatal brains demonstrate the
opposite as the depletion of these cells enhances injury by removing endogenous
protective mechanisms (Faustino, Wang et al. 2011).
Scavenger receptor CD36, a trans-membrane glycoprotein, is involved in several
biological functions, such as foam cell formation, immune cell chemotaxis, and
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phagocytosis of apoptotic cells (Woo, Wang et al. 2012). CD36 receptor is reportedly
located on the cell surface of several cell types, including monocytes, endothelial cells,
and microglia. CD36 plays an important role in phagocytosis, and upregulating its
expression beneficially enhances hematoma resolution (Zhao, Sun et al. 2007).
Transfection of non-phagocytic cells with a CD36-expressing gene converted those cells
into phagocytes (Ren, Silverstein et al. 1995). CD36 genetic deletion worsened injury
after acute focal stroke in neonatal mice, partially by decreasing removal of apoptotic
cells (Woo, Wang et al. 2012).
Peroxisome proliferator-activated receptor gamma (PPAR), a member of the
nuclear hormone receptor superfamily, plays a major role in the upregulating CD36
expression (Zhao, Sun et al. 2007; Zhao, Grotta et al. 2009). PPAR stimulation exerts
anti-inflammatory effects in several central nervous system injuries and disorders
(Pereira, Hurtado et al. 2005; Landreth, Jiang et al. 2008). Many studies demonstrated
PPAR is neuroprotective in various experimental stroke models (Pereira, Hurtado et al.
2005; Zhao, Sun et al. 2007; Woo, Wang et al. 2012; Shao and Liu 2015). In adult
intracerebral hemorrhage (ICH) experimental models, PPAR activation was directly
associated with upregulation of CD36 expression, leading to enhanced phagocytosismediated clearance of the hematoma as well as dead or damaged cells by microglia and
macrophages. PPAR stimulation reduced expression of pro-inflammatory mediators,
ameliorated secondary brain injury, and improved functional recovery after ICH (Zhao,
Sun et al. 2007). Currently, PPAR stimulation for enhancing hematoma resolution and
ameliorating secondary brain injury is being clinically tested in ICH patients (Gonzales,
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Shah et al. 2013). Yet, no clinical trials are evaluating PPAR stimulation in GMH
patients.
In this study, we assess if PPAR stimulation enhances CD36-mediated
hematoma resolution in a neonatal rat germinal matrix hemorrhage model. We
hypothesize PPARγ stimulation, using 15d-PGJ2, will augment microglia/macrophage
phagocytosis of blood clots, reducing post-hemorrhagic hydrocephalus, inflammation,
behavioral dysfunction, and neuronal loss, which will be reversed by CD36 knockdown
or PPAR antagonist administration.

Materials and methods
Animals and Surgeries
All experimental procedures were conducted in accordance with the National
Institutes of Health guidelines for the treatment of animals, and were approved by the
Institutional Animal Care and Use Committee of Loma Linda University. Two hundred
and sixty P7 Sprague-Dawley neonatal pups (Harlan, Indianapolis, IN) weighing 12-15 g
(brain development is comparable to 30-32 week gestation humans) were used in this
study. Germinal matrix hemorrhage was achieved by stereotactic-guided injection of
bacterial collagenase, as previously described (Lekic, Manaenko et al. 2012). Pups were
anesthetized with 3% isoflurane (delivered through medical grade oxygen and mixed air)
while being stabilized onto a stereotaxic frame. Isopropyl alcohol followed by betadine
was applied to the incision site. Incision was made on the longitudinal plane to expose the
skull and reveal bregma. The stereotactic coordinates from bregma were as follows: 1.6
mm (rostral), 1.6 mm (right lateral), and 2.8 mm (depth) from the dura. A burr hole (1
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mm) was drilled, into which a 27 gauge needle was inserted at a rate of 1 mm/min. 0.3
units of clostridial collagenase VII-S (Sigma Aldrich, MO) in 1 µL was infused over a
period of 3 minutes with a Hamilton syringe guided by a microinfusion pump (Harvard
Apparatus, Holliston, MA). After completing infusion, the needle is left into position for
an additional 10 minutes after injection to prevent “back-leakage” and then removed at a
rate of 1 mm/min. Once the Hamilton is removed, the burr hole is sealed with bone wax
and the incision site sutured. Animals are then given buprenorphine and allowed to
recover on a 37°C heated blanket. When fully recovered, pups are then placed back with
the mother. Surgery time per animal is approximately 30 minutes. Sham animals were
subject to needle insertion without collagenase infusion. The same procedures were
performed for intraventricular injection of siRNA, except the stereotactic coordinates
from bregma were as follows: 1.0 mm (rostral), 1.0 mm (left lateral), and 1.8 mm (depth)
of the dura.

Animal Treatments and Experimental Groups
P7 rat pups were randomly divided into the following groups: sham-operated
(n=38), Vehicle (n=38), GMH + 15d-PGJ2 (n=38), GMH + 15d-PGJ2 + GW9662 (n=38),
GMH + CD36 siRNA (n=12), GMH + 15d-PGJ2 + CD36 (n=12), GMH + scrambled
siRNA (n=12). The PPARγ agonist (15d-PGJ2, 0.1mg/kg; Sigma Aldrich), antagonist
(GW9662, 4mg/kg; Sigma Aldrich) + agonist, and saline (for sham and vehicle groups)
were administered intraperitoneally to experimental animals at 1 hour post-GMH and
then once daily for 7 days. CD36 siRNA (1.2 ng, Cell Signaling & Santa Cruz), and
scrambled siRNA (1.2 ng, Santa Cruz) were administered via intraventricular injection to
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experimental animals 24 hours prior to GMH induction. Buprenorphine (0.01 mg/kg) was
administered subcutaneously to all groups after completing surgery.

Animal Perfusion and Tissue Extraction
Animals were euthanized using isoflurane (≥5%) followed by trans-cardiac
perfusion with ice-cold phosphate buffered saline (PBS) for hemoglobin assay and
Western blot samples or with ice-cold PBS followed by 10% formalin for histology
samples. Forebrains for hemoglobin assay and Western blot were snap-frozen with
liquid-nitrogen, then stored in -80°C freezer before protein extractions or
spectrophotometric quantification. Histological brain samples were post-fixed in 10%
Fomaldehyde for at least 3 days and then 30% sucrose for at least 3 days, all stored in
4°C fridge. Forebrains were next embedded in Optimal Cutting Temperature compound
and stored in -20°C freezer.

Hemoglobin Assay
Spectrophotometric measurements were used to assess hemorrhagic volume using
well-established protocols (Choudhri, Hoh et al. 1997; Tang, Liu et al. 2004; Lekic,
Manaenko et al. 2011). Frozen extracted forebrains were placed into individual glass
tubes containing 3 mL of PBS. The tissue was homogenized for 60 seconds (Tissue Miser
Homogenizer; Fisher Scientific, Pittsburgh, PA) followed by ultrasonication for 1 minute
to lyse erythrocyte membranes. The products were then centrifuged for 30 minutes and
the supernatant was separated from the pellets. A 4:1 ratio of Drabkin’s reagent (SigmaAldrich) and supernatant were combined, which were left to react for 15 minutes.
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Absorbance, using a spectrophotometer (540 nm; Genesis 10uv; Thermo Fisher
Scientific, Waltham, MA), was calculated into a hemorrhagic volume (μL) on the basis of
a standard curve as routinely performed (Lekic, Manaenko et al. 2011).

Intracranial Pressure (ICP) Measurements
At 28 days post-ictus, animals were anesthetized and mounted onto a stereotaxic
frame, where the head was inclined downward at a 30 degree angle. A midline skin
incision was made to expose the atlanto-occipital membrane. The cisterna magna was
punctured with a 26G Hamilton needle, which was connected to a pressure transducer of
a Digi-Med LPA 400-low pressure Anayzer (Micro-Med-Louisville, Kentucky, USA) as
described (Lackner, Vahmjanin et al. 2013)

Western Blotting
Protein concentrations for immunoblot (Lekic, Manaenko et al. 2011) were
determined by DC protein assay (Bio-Rad, Hercules, CA). 30 µg protein per sample were
loaded into wells of 4-20% gels, ran for 30 minutes at 50V then 90 minutes at 125V, then
transferred onto nitrocellulose membranes at 0.3A for 120 minutes (Bio-Rad).
Membranes were incubated for 2 hours in 5% non-fat milk in Tris-buffered saline
containing 0.1% Tween20. Then the following primary antibodies were incubated
overnight: anti-PPARy (1:1000; Santa Cruz, Dallas, Texas), CD36 (1:500, Santa Cruz,
Dallas, Texas), and mannose receptor (CD206) (1:500, ABcam, Cambridge,
Massachusetts). Secondary antibodies (1:2000; Santa Cruz Biotechnology, Santa Cruz,
CA) were then applied to the membranes and incubated for 2 hours and then processed
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with the ECL plus Kit (GE Healthcare and Life Science, Piscataway, NJ). β-actin was
used as an internal control against the anti-body (1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA). ImageJ software (4.0, Media Cybernetics, Silver Spring, MD) was used
to analyze the relative density of the resultant protein immunoblot images as described
(Tang, Liu et al. 2004).

Histological Volumetric Analysis
10 μm thick coronal brain sections were cut every 600 μm using a cryostat (Leica
Microsystems LM3050S) and were placed onto poly-L-lysine-coated slides. Brain slices
were Nissl stained morphometrically analyzed using computer-assisted (ImageJ 4.0,
Media Cybernetics, Silver Spring, MD) hand delineation of the ventricle system (lateral,
third, cerebral aqueduct, and fourth), hemisphere (cortex, subcortex), caudate, thalamus,
hippocampus, and corpus callosum (white matter) (Lekic, Manaenko et al. 2011). These
structures were delineated using optical dissector principles from prior stereological
studies (Reisert, Wildemann et al. 1984; Oorschot 1996; Tang, Lopez et al. 2001;
Bermejo, Jimenez et al. 2003; Avendano, Machin et al. 2005; Ekinci, Acer et al. 2008;
Klebe, Krafft et al. 2014). Volumes were calculated using the following equation:
[(Average [(Area of coronal section) × Interval × Number of sections) (MacLellan, Silasi
et al. 2008).

Immunohistochemistry
10 μm thick slices were first stained with OX-42 (1:1000, ABcam) and mannose
receptor (1:1000, ABcam) overnight at 4 °C, followed by incubation with appropriate
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fluorescence conjugated secondary antibodies (Jackson Immunoresearch, West Grove,
PA). The peri-hemorrhagic area was imaged by a Fluorescent Olympus-BX51
microscope and analyzed using MagnaFire SP 2.1B software (Olympus, Melville, NY).
At least six sections per animal group over a microscopic field of 20 × (for microglia)
were averaged and expressed as cells/field, as described (Wang and Dore 2007).

Neurobehavioral Analysis
Neurobehavioral function was evaluated in a blinded manner using a battery of
tests, described below, to detect sensorimotor and cognitive deficits 28 days after GMH
as previously described (Hartman, Lekic et al. 2009; Klebe, Krafft et al. 2014): Foot Fault
Test: Rats were placed on a wire grid (20x40 cm) kept above the floor level and allowed
to walk on the grid for 2 minutes. Number of foot faults will be recorded when a
complete paw falls through the openings in the grid. Rotarod Test: Rats were placed on a
rotarod (Columbus Instruments, Columbus, OH), which consists of a rotating horizontal
cylinder (7 cm diameter) divided into 9.5-cm-wide lanes. Rats walked forward when the
cylinder is rotating to avoid falling down. Rats were tested at a starting 5 RPM or 10
RPM with acceleration at 2 RPM per 5 seconds. A photobeam circuit detected the latency
to fall off the cylinder. Water Maze Test: Rats were released in a metal pool (110 cm
diameter) filled with water and containing spatial cues on the walls, and they were
allowed to swim to find a submerged platform (11 cm diameter). Each animal performed
10 trials per day for 4 days, 5 blocks of 2 consecutive trials, with a 10-min interval
between successive blocks. Over the next 3 days, the platform was submerged 1 cm
below the water and surface and the rats had to find and remember the platform location.
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Additionally, at the end of each day, the platform was removed and animals were allowed
to swim to find the platform quadrant. An overhead camera with a computerized tracking
system (Noldus Ethovision; Noldus, Tacoma, WA) recorded the swim path and measured
the swim distance, swim speed, and time spent in probe quadrant.

Statistical Analysis
A power analysis using a type I error rate of 0.05 and a power of 0.8 on a 2-sided
test was used to estimate sample size. Data are expressed in Mean ± Standard Deviation.
One-way ANOVA on ranks using the Student-Newman-Keuls post-hoc test was used to
analyze behavioral, histological, western blots, and immunohistochemistry. A P-value
<0.05 was considered statistically significant.

Results
PPAR Stimulation Ameliorated Long-term Neurological Deficits
The vehicle group performed significantly worse compared to sham in the Morris
Water Maze evaluation, yet PPARγ stimulation improved spatial learning and memory
compared to vehicle and was not significantly different from sham. Treatment effect was
reversed by the PPAR antagonist (*P<0.05 versus Sham; #P<0.05 versus Vehicle;
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.1.A-B). Treatment also significantly
improved sensorimotor function in the foot fault test compared to other GMH groups
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2;
Figure 2.1.C). Yet no significant difference was achieved in the treated group compared
to vehicle and antagonist groups in the rotarod sensorimotor evaluation (*P<0.05 versus
Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.1.D).
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Figure 2.1: Long-term neurocognitive and sensorimotor outcomes after 15d-PGJ2
treatment and PPARγ inhibition with 15d-PGJ2 treatment at 3-4 weeks after GMH.
Neurofunctional assessment of (A and B) Morris water maze, (C) foot fault, and (D)
rotarod at 21 to 28 days after germinal matrix hemorrhage. Values are expressed as
mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, and †P<0.05
compared with inhibitor and agonist. N=8 per group; and RPM, rounds per minute.
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PPAR Stimulation Improved Long-term Brain Morphology
Since increased intracranial pressure is associated with hydrocephalus, ICP was
measured in rats at 4 weeks post-ictus. ICP was significantly decreased in treated groups
when compared to vehicle and PPAR antagonist groups (*P<0.05 versus Sham; #P<0.05
versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.2.B). Calculated cortical
thickness is presented as a ratio to the mean of sham and was significantly deceased in
the vehicle and PPAR antagonist group, but the PPAR stimulated group had
significantly less cortical loss (*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05
versus GW9662 + 15d-PGJ2; Figure 2.3.A). Ventricular volume was significantly
increased in vehicle and PPAR antagonist groups, but 15d-PGJ2 treatment reduced posthemorrhagic ventricular dilation (*P<0.05 versus Sham; #P<0.05 versus Vehicle;
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.3.B). White matter loss is presented as a
percentage of white matter present to mean of sham. White matter loss was reduced by
PPAR stimulation, but vehicle and PPAR antagonist groups had significant white
matter loss (*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 +
15d-PGJ2; Figure 2.3.C). Basal ganglia loss is presented as a percentage of basal ganglia
present to mean of sham. The 15d-PGJ2 treated group had significantly decreased basal
ganglia loss compared to the vehicle group. Surprisingly, basal ganglia loss in the
GW9662 group was not significantly different from PPAR agonist or vehicle groups
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2;
Figure 2.3.D).
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Figure 2.2: Effects of 15d-PGJ2 treatment and PPARγ inhibition with 15d-PGJ2
treatment on brain morphology and intracranial pressure 4 weeks after GMH. 28
days after germinal matrix hemorrhage. Representative microphotographs of (A) Nisslstained brain sections were taken and (B) Intracranial pressure (ICP) in mm Hg. Note:
measurement on the right side of the representative pictures indicates the location of the
brain section from bregma. Values are expressed as mean±SD. *P<0.05 compared with
sham, #P<0.05 compared with vehicle, and †P<0.05 compared with inhibitor and agonist.
N=6 per group; and mmHG, millimeters of Mercury.
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Figure 2.3: Quantification of brain morphological outcomes from 15d-PGJ2
treatment and PPARγ inhibition with 15d-PGJ2 treatment at 4 weeks post-GMH.
Quantification of (A) cortical thickness, (B) ventricular volume, (C) white matter loss,
and (D) basal ganglia loss at 28 days after germinal matrix hemorrhage. Values are
expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle,
and †P<0.05 compared with inhibitor and agonist. N=6 per group.
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PPAR Stimulation Enhanced Hematoma Resolution, Increased Activated
Microglia, and Induced M2 Polarization
A hemoglobin assay time-course was conducted at 24 hours, 72 hours, and 7 days
to determine PPAR’s role in hematoma resolution. At 24 hours, all groups had
significantly greater hemoglobin content in the brain compared to sham (*P<0.05 versus
Sham; Figure 2.4.A). At 72 hours, all groups had significantly greater hemoglobin
content in the brain compared to sham, but 15d-PGJ2 treatment had significantly less
hemoglobin content compared to vehicle, which was reversed by GW9662 treatment
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2;
Figure 2.4.B). At 7 days, only the vehicle and PPAR antagonist groups had significantly
greater hemoglobin content compared to sham, but the PPAR agonist group had
significantly less hemoglobin content compared to vehicle and PPAR antagonist groups
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2;
Figure 2.4.C). Since significantly greater hematoma resolution was observed in the
PPAR stimulated group at 72 hours, representative photographs of immuno-stained
activated microglia/macrophages (OX-42) in the peri-hematoma region are presented at
this time point (Figure 2.5.A). The 15d-PGJ2 treated group had relatively increased
number of microglia/macrophage compared to sham, vehicle, and PPARγ antagonist
group ((*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15dPGJ2; Figure 2.5.B). Additionally representative photographs of the co-localization of
activated microglia/macrophages (OX-42) and mannose receptor (CD206) in the perihematoma region are presented at 72 hours, showing an increase in OX-42/mannose
receptor expression in 15d-PGJ2 treated group in comparison to all other groups (Figure
2.5.A).
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Figure 2.4: Short-term hematoma resolution after GMH from 15d-PGJ2 treatment,
PPARγ inhibition with 15d-PGJ2 treatment, CD36 knockdown, and CD36
knockdown with 15d-PGJ2 treatment. Hemoglobin assay at (A) 24 hours, (B) 72 hours,
and (C) 7 days. At 72 hours (D) Hemoglobin assay was conducted on siRNA groups.
Values are expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared
with vehicle, and †P<0.05 compared with inhibitor and agonist, %P<0.05 compared CD
36 siRNA, and @P<0.05 compared to scrambled siRNA. N=6 per group.
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Figure 2.5: Microglia / Macrophage activation and differentiation into M2 subtypes
at 3 days post-GMH following 15d-PGJ2 treatment, CD36 knockdown, and CD36
knockdown with 15d-PGJ2 treatment. Immunohistochemistry representative pictures
were taken showing the co-localization of (A) activated microglia (OX-42; scale bar:
20 µm) with Mannose Receptor and DAPI staining and (B) quantification of activated
microglia was conducted at 72 hours. Western blots were conducted at 72 hours for (C)
CD206 Expression. Note: peri-hematoma region is below the yellow broken line (A) and
the representative GMH brain indicates where IHC images were taken. Values are
expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle,
†P<0.05 compared with inhibitor and agonist, %P<0.05 compared CD36 siRNA, and
@P<0.05 compared to scrambled siRNA. N=6 per group; and ICH,
Immunohistochemistry. N=6 per group.
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PPARγ Stimulation Increased CD36 and PPARγ Expression at 72 Hours
A time-course study was conducted to determine endogenous PPARγ and CD36
expression levels in GMH at 0, 3, 6, 12 hours and 1, 3, 5, and 7 days after GMH.
Endogenous PPARγ expression was significantly increased at 3, 6, 12 hours and 1 day
compared to 0 hour (*P<0.05 versus 0 hours; Figure 2.6.A). Correspondingly,
endogenous CD36 expression was significantly increased at 3, 6, 12 hours, and 1 day
compared to 0 hour (*P<0.05 versus 0 hours; Figure 2.6.B), and tended to remain
elevated by 7 days. PPARγ and CD36 expression levels were determined at 72 hours for
all experimental groups. PPARγ expression was significantly increased in the 15d-PGJ2
group compared to all other groups (*P<0.05 versus Sham; #P<0.05 versus Vehicle;
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.6.C). Much like PPARγ, CD36 expression
was significantly increased in the 15d-PGJ2 group compared to all other groups (*P<0.05
versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure
2.6.D).
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Figure 2.6: Short-term time course of CD36 and PPARγ expression after GMH and
the effects of 15d-PGJ2 treatment, PPARγ inhibition with 15d-PGJ2 treatment,
CD36 knockdown, and CD36 knockdown with 15d-PGJ2 treatment on CD36 and
PPARγ expression levels. Western blot was conducted for time-course studies of (A)
PPARγ and (B) CD36 at 0, 3, 6 , 12 hours, 1, 3, 5, 7 days after GMH. Western blot was
then conducted at 72 hours for (C) PPAR-Υ and (D) CD36. Values are expressed as
mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, and †P<0.05
compared with inhibitor and agonist. N=6 per group; and h and d, hour(s) and day(s).
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CD36 Knockdown Reversed PPAR Agonist-enhanced Hematoma Resolution
and M2 Expression at 72 Hours
At 72 hours, CD36 knockdown reversed PPARγ agonist-enhanced hematoma
resolution, which was not reversed in the scrambled siRNA group (*P<0.05 versus Sham,
#P<0.05 versus Vehicle, %P<0.05 versus CD-36 siRNA + 15d-PGJ2, @P<0.05 versus
scrambled siRNA+15d-PGJ2, Figure 2.4.D). Additionally, CD36 knockdown reversed
PPARγ mannose receptor expression, which was not reversed in the scrambled siRNA
group (*P<0.05 versus Sham, #P<0.05 versus Vehicle, %P<0.05 versus CD-36 siRNA +
15d-PGJ2, @P<0.05 versus scrambled siRNA+15d-PGJ2, Figure 2.5.C).

Discussion
Neonatal brain hemorrhage is a common affliction of premature infants. The
resultant hematoma is thought to play a major role in causing post-hemorrhagic
hydrocephalus development because blood clots disrupt cerebrospinal fluid circulation
and absorption in the ventricles (Crews, Wyss-Coray et al. 2004). Rapid hematoma
resolution was neuroprotective in adult hemorrhagic stroke models (Zhao, Sun et al.
2007; Zhao, Sun et al. 2015). In particular, PPARγ stimulation upregulates CD36
expression in microglia/macrophages, leading to increased phagocytosis of blood
products and more rapid hematoma resolution after adult intracerebral hemorrhage (Zhao,
Sun et al. 2007). In this study, we examined the effects of stimulating PPARγ with 15dPGJ2 on hematoma resolution as well as long-term brain morphological and
neurofunctional outcomes after collagenase-induced GMH in neonatal rats. In addition,
we determined if PPARγ and CD36 inhibition reversed observed therapeutic effects from
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PPARγ stimulation by 15d-PDJ2. This study is the first to assess this treatment approach
in neonates for enhancing hematoma resolution as well as the first to evaluate its
therapeutic potential for ameliorating long-term white matter loss, post-hemorrhagic
hydrocephalus development, and neurological deficits.
We evaluated the efficacy of 15d-PGJ2 treatment, a PPARγ agonist, administered
1 hour post-ictus as a potential therapeutic modality for GMH-induced brain injury.
Although treatment did not significantly increase hematoma resolution at 24 hours, it did
significantly enhance hematoma resolution at 72 hours and 7 days after GMH (Figure
2.4.A-C). PPARγ stimulation demonstrated more rapid hematoma clearance after GMH
in neonates, starting at 72 hours, than after ICH in adults, which took 7 days (Zhao, Sun
et al. 2007). 15d-PGJ2 co-admiration with GW9662, a PPARγ antagonist, reversed 15dPGJ2 treatment effects on enhanced hematoma resolution at 72 hours and 7 days after
GMH. To determine if endogenous expression of PPARγ and CD36 changes after GMH,
we performed a Western blot time course using 0, 3, 6, 12 hour, 1, 3, 5, and 7 day
endpoints following GMH induction. Endogenous PPARγ expression increased at 3, 6,
12 hour, and 1 day after GMH induction, then returned to baseline by 3 days (Figure
2.6.A). Endogenous CD36 expression significantly increased at 3, 6, 12 hours, and 1 day
after GMH induction, and tended to remain elevated through 7 days (Figure 2.6.B).
Because endogenous PPARγ and CD36 expression returned near baseline at 72 hours and
because 15d-PGJ2 treatment enhanced hematoma resolution at 72 hours, we determined
treatment effects on PPARγ and CD36 expression levels by Western blot at 72 hours. As
expected, 15d-PGJ2 treatment significantly increased PPARγ expression compared to
sham and vehicle, and 15d-PGJ2 co-administration with GW9662 reversed this effect
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(Figure 2.6.C). Similarly, 15d-PGJ2 treatment significantly increased CD36 expression
compared to sham and vehicle, and 15d-PGJ2 co-administration with GW9662 reversed
this effect (Figure 2.6.D).
CD36 receptor is an important scavenger receptor located on several cell types,
including monocytes, endothelial cells, and microglia/macrophages. CD36 plays an
important role in microglia/macrophage phagocytosis, and upregulating its expression
beneficially enhances hematoma resolution (Zhao, Sun et al. 2007). More activated
microglia were observed in the peri-hematoma region of treated GMH animals than all
other groups, providing evidence of PPARγ’s treatment effects are dependent upon these
critical immune cells (Figure 2.5.A-B). All GMH groups seemed to have increased DAPI
stained cells post-ictus compared to sham. The germinal matrix has many growing and
dividing neuronal and glial precursor cells. Prior GMH studies have documented
increased proliferative cytokines and pathways, such as TGF-β and mTOR, after injury,
and we speculate proliferative signaling triggers more profound gliosis after neonatal
brain hemorrhage (Lekic, Klebe et al. 2015). While brain cell death is definitely
occurring, we speculate proliferative signaling in conjunction with increased leukocyte
infiltration contributes towards these observed results in neonatal brains. Although
activated microglia/macrophages contribute to brain injury in adults, some evidence
suggests microglia/macrophages have important defense mechanisms against injury in
neonates, which could be explained by the vital role microglia play in neonatal brain
development (Faustino, Wang et al. 2011; Harry and Kraft 2012). Furthermore, activated
microglia/macrophages have two differentiated states, a pro-inflammatory classically
activated state (M1), and an immune dampening and tissue regenerative alternatively
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activated state (M2) (Klebe, McBride et al. 2015). CD36 stimulation can contribute
towards microglia/macrophage activation as well as M2 polarization (Kouadir, Yang et
al. 2012; Rios, Koga et al. 2013; Chavez-Sanchez, Garza-Reyes et al. 2014). PPARγ
stimulation also polarizes microglia/macrophages towards the M2 state (Yoon, Jeon et al.
2008; Pisanu, Lecca et al. 2014; Penas, Mirkin et al. 2015). To corroborate these findings
in GMH, immunohistochemical co-localization of activated microglia and mannose
receptor (CD206), an M2 marker, demonstrated increased co-expression in 15d-PGJ2
treated GMH animals compared to other groups, providing more evidence PPARγ
induces M2 polarization (Figure 2.5.A). Similarly, CD206 Western blots demonstrated
increased CD206 expression levels in treated GMH animals compared to sham, GMH
animals with CD36 siRNA alone, and GMH animals with CD36 siRNA and 15d-PGJ2
treatment. Interestingly, vehicle treated GMH animals showed a small tendency towards
having increased CD206 expression levels, which also did not achieve a statistically
significant difference compared to 15d-PGJ2 treated GMH animals. After hemorrhage,
M2 microglia/macrophages are expected to increase over time as the peri-hematoma
milieu transitions into an immune dampened tissue repair phase in which M2
microglia/macrophages play a pivotal role (Klebe, McBride et al. 2015). CD36
knockdown eliminated the tendency observed in the vehicle group, achieving a
significantly reduced expression compared to 15d-PGJ2 treatment. CD36 knockdown also
reversed 15d-PGJ2 induced upregulation of CD206 expression (Figure 2.5.C). CD36,
thus, is important for M2 polarization, particularly after PPARγ stimulation. To further
confirm microglial/macrophage CD36 plays a pivotal role in PPARγ-induced blood clot
clearance, siRNA was used to knockdown CD36 expression. CD36 knockdown reversed
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15d-PGJ2 treatment effects on enhanced hematoma resolution at 72 hours, which was not
reversed by scrambled siRNA (Figure 2.4.D).
In our long-term evaluations, vehicle treated GMH animals had significant
cortical, white matter, and basal ganglia loss as well as post-hemorrhagic ventricular
dilation, but 15d-PGJ2 treatment ameliorated these brain morphological maladies, which
were reversed by PPARγ antagonist, GW9662, co-administration (Figure 2.3.A-D).
Surprisingly, GW9662 co-administration did not completely reverse 15d-PGJ2’s effects
on reducing basal ganglia loss, although a tendency was observed. Our ICP
measurements agreed with the brain morphological assessment, where ICP levels were
significantly lower in treated groups when compared to vehicle and PPARγ antagonist
group (Figure 2.2.B). Additionally, vehicle treated GMH animals performed poorly in the
Morris Water Maze, Foot Fault, and Rotarod tests, but 15d-PGJ2 treatment significantly
improved spatial memory and motor function, which were reversed by GW9662 coadministration (Figure 2.1.A-D). The foot fault test evaluates locomotor function, the
rotarod test evaluates sensorimotor coordination and balance, and Morris Water Maze
evaluates spatial learning and memory (Schaar, Brenneman et al. 2010). Although 15dPGJ2 reduced the number of foot faults, it did not significantly improve performance in
the rotarod test. GMH and consequent post-hemorrhagic ventricular dilation may cause
cerebellar injury that affects motor coordination (Volpe 2009; Brouwer, de Vries et al.
2015; Fumagalli, Bassi et al. 2015). More thorough investigations are needed to elucidate
the pathophysiology between GMH and cerebellar injury. Although motor coordination is
an important factor in both the rotarod and foot fault tests, the element of balancing on an
accelerating cylinder platform leads us to speculate cerebellar injury may more
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profoundly affect performances in the rotarod evaluations. 15d-PGJ2 treatment may not
be effective enough to ameliorate potential cerebellar injury from GMH and consequent
post-hemorrhagic hydrocephalus, and, if this is the case, modulating the immune
response after GMH may not be sufficient to promote complete functional recovery.
Additionally, the rotarod test may not be sensitive enough for detecting improved
sensorimotor outcomes in treatment groups, which is why we performed multiple
neurofunctional evaluations. Nonetheless, these results provide sufficient evidence that
enhanced hematoma resolution corresponds with improved long-term brain
morphological and neurocognitive outcomes after GMH. Most importantly, more rapid
blood clot clearance resulted in significantly decreased post-hemorrhagic ventricular
dilation, providing evidence that blood products play an important role in posthemorrhagic hydrocephalus development.
The CD36 scavenger receptor is important in microglia/macrophage-mediated
phagocytosis of cellular debris and blood products. Our results suggest PPARγ
stimulation by 15d-PGJ2 increases microglia/macrophage phagocytic function by
upregulating CD36 scavenger receptor expression in our experimental GMH model,
leading to enhanced hematoma resolution. We are first to report the positive long-term
effects on brain morphological and neurofunctional outcomes from more efficient
hematoma resolution after GMH. Blood products disrupt cerebrospinal circulation and
absorption in the cerebroventricular system, often resulting in post-hemorrhagic
hydrocephalus. Herein, we provide evidence that more rapid blood clot clearance
reduces long-term post-hemorrhagic ventricular dilation after GMH. Removing the
hematoma without damaging surrounding tissues is ideal and clinically relevant. PPARγ
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stimulation could be a promising therapeutic approach for GMH patients, especially since
PPARγ stimulation by Pioglitazone is already being evaluated in clinical trials for adult
cerebral hemorrhage.
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Abstract
This study investigated if acute and delayed Deferoxamine treatment attenuates
long-term sequelae after germinal matrix hemorrhage (GMH). Bacterial collagenase (0.3
U) was infused intraparenchymally into the right hemispheric ganglionic eminence in P7
rat pups to induce GMH. GMH animals received either Deferoxamine or vehicle twice a
day for 7 consecutive days. Deferoxamine administration was initiated at either 1 hour or
72 hours post-GMH. Long-term neurocognitive deficits and motor coordination were
assessed using Morris water maze, rotarod, and foot fault tests between day 21-28 postGMH. At 28 days post-GMH, brain morphology was assessed and extracellular matrix
protein (fibronectin and vitronectin) expression was determined. Acute and delayed
Deferoxamine treatment improved long-term motor and cognitive function at 21-28 days
post-GMH. Attenuated neurofunction was paralleled with improved overall brain
morphology at 28 days post-GMH, reducing white matter loss, basal ganglia loss, posthemorrhagic ventricular dilation, and cortical loss. GMH resulted in significantly
increased expression of fibronectin and vitronectin, which was reversed by acute and
delayed Deferoxamine treatment. Acute and delayed Deferoxamine administration
ameliorated long-term sequelae after GMH.
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Introduction
Germinal matrix hemorrhage (GMH) occurs when immature blood vessels
rupture within the subventricular tissue in premature infants (Ballabh 2010). GMH
occurs in approximately 12000 live births per every year in the US and often results in
developmental delays, mental retardation, cerebral palsy, and post-hemorrhagic
hydrocephalus, posing significant socioeconomic burdens (Ballabh 2010; Kochanek,
Kirmeyer et al. 2012). Because current clinical management is limited, research is
needed to investigate innovative therapeutic modalities.
In adult rodent intracerebral hemorrhage and subarachnoid hemorrhage models,
red blood cells present in the intraparenchymal tissue are lysed and hemoglobin
metabolized to release iron, resulting in a highly oxidative environment and consequent
iron toxicity that damages brain tissue (Lee, Keep et al. 2010; Xiong, Wang et al. 2013).
Chelation of iron using Deferoxamine improved neurofunctional outcomes after
intracerebral hemorrhage and subarachnoid hemorrhage, yet its efficacy has not been
evaluated after neonatal GMH (Lee, Keep et al. 2011; Hatakeyama, Okauchi et al. 2013).
Blood products and proliferation of extracellular matrix proteins are theorized to disrupt
CSF flow dynamics following hemorrhage, leading to consequent post-hemorrhagic
hydrocephalus development (Crews, Wyss-Coray et al. 2004).
We hypothesized acute and delayed Deferoxamine treatment will ameliorate extracellular
matrix protein proliferation, post-hemorrhagic ventricular dilation, and long-term
neurofunctional outcomes after GMH.
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Materials and Methods
Animal Surgery and Experimental Groups
All protocols and procedures were approved by the Institutional Animal Care and
Use Committee at Loma Linda University. Timed-pregnant rats were purchased from
Harlan Laboratories (Indianapolis, IN). Stereotaxic infusion of 0.3 U bacterial
collagenase into the right ganglionic eminence was performed to induce GMH in P7 rat
pups, as described (Lekic, Manaenko et al. 2012). While some consider P7 rat pups to be
equivalent in brain development of a term human infant, recent evidence suggests P7 is
closer in brain development to 30-32 week gestation age human infants, which is
approximately the point we want to model GMH (Lekic, Manaenko et al. 2012). Briefly,
rat pups were anesthetized with isoflurane (3 % in a 30/70 oxygen/medical air mixture)
and placed prone with their head secured onto a rodent stereotaxic frame. After sterilizing
the rodent’s scalp, a small midline incision was made to expose bregma. Next, a cranial
burr hole was made 1.8 mm rostral and 1.5 mm right lateral from bregma, using a
standard dental drill (1 mm). A 26-gauge needle was inserted through the cranial burr
hole and stereotactically lowered 2.8 mm into the brain parenchyma. Following that,
bacterial collagenase VII-S (0.3 U, Sigma; St. Louis, MO) was infused into the right
hemispheric ganglionic eminence, at a rate of 0.25 µl/minute. Back-leakage of
collagenase was prevented by keeping the needle in place for 10 minutes after completed
infusion. Following that, the needle was withdrawn at a rate of 1 mm/minute, the burr
hole was sealed with bone wax, and the scalp sutured. Sham animals were subjected to
needle insertion only. Rat pups were returned to their dams after full recovery from the
anesthesia. Forty animals were divided into four groups: Sham, Vehicle (PBS
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intraperitoneally BID starting 1 hour post-GMH for 7 days), acute Deferoxamine (100
mg/kg intraperitoneally BID starting 1 hour post-GMH for 7 days), and delayed
Deferoxamine (100 mg/kg intraperitoneally BID starting 72 hours post-GMH for 7 days).
Each animal group was alternated when undergoing surgeries. Blinded investigators
performed the neurobehavioral, histological, and Western blot analyses.

Behavioral Testing
Neurocognitive deficits and motor coordination were evaluated by Morris water
maze, rotarod, and foot fault tests between 21-28 days post-GMH (n=10/group). The
mentioned neurofunctional tests have been previously utilized for the evaluation of longterm deficits in rodents subjected to unilateral hemorrhagic brain injury (Lekic,
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Rolland, Lekic et al. 2013). All tests
were conducted in a blinded fashion. Learning and memory abilities in rats were assessed
via the Morris water maze by measuring (1) the swim distance for each animal before
detecting a slightly submerged platform in a pool of water (diameter: 110 cm) and (2) the
time each animal spent searching the target quadrant, after the platform has been removed
from the pool (probe trial). An overhead infrared camera linked to a computerized
tracking system (Noldus Ethovision, Tacoma, WA) recorded the swim path and time of
each animal. The water maze experiments were conducted on day 21 to 25 post-GMH
induction, one block per day followed by the probe trial. Animals that failed to swim or
only swam in stationary circles were excluded from further analysis in our study. Motor
and coordination function were evaluated on post-operative days 26 to 28. The rotarod
apparatus (Columbus Instruments, Columbus, OH), consisting of horizontally rotating
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cylinders (7 cm in diameter, 9.5 cm in width) rotate either at constant velocity or
accelerate 2 RPM every 5 seconds starting at a speed of 5 or 10 RPM. Continuous
walking was required to avoid falling; the latency to fall was recorded for each animal by
a photobeam circuit. Foot-fault testing was conducted by placing each animal on a
horizontally elevated wire-grid (20 cm x 100 cm) and missteps through the grid were
recorded over 2 minutes.

Histopathological Analysis
Ventricular volume, cortical thickness, white matter loss, and basal ganglia loss were
calculated in Nissl stained histological brain sections 28 days post-GMH using NIH
Image J software (n=5/group). Brain tissue preparation, staining, and volumetric
evaluations were conducted as previously described (Lekic, Manaenko et al. 2012;
Leitzke, Rolland et al. 2013). Briefly, animals under deep isoflurane anesthesia were
euthanized by transcardiac perfusion with PBS and 4% paraformaldehyde. Following
that, brains were collected, formalin fixed (in 4% paraformaldehyde for 3 days),
dehydrated (in 30 % sucrose for 3 days), and frozen coronal brain slices (10 µl) were
obtained, using a cryostat (CM3050S; Leica Microsystems). Nissl stained histological
brain sections were evaluated via computer assisted (Image J) hand delineation of
cerebral and cerebroventricular structures, based on criteria from stereologic studies
using optical dissector principles (Oorschot 1996; Ekinci, Acer et al. 2008). Volumes
were calculated as the average delineated area from 10 μm sections taken at
approximately 2.5 mm, 1.2 mm, 0.7 mm rostral and 2.9 mm caudal of bregma multiplied
by the depth of the cerebroventricular system. The ventricular volume (mm3) was
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calculated as average ventricular area multiplied by the depth of the cerebroventricular
system. The cortical thickness was calculated and expressed as ratio of the contralateral
brain cortex. Basal ganglia volumes and white matter loss were expressed as % of the
sham group. Basal ganglia and white matter volumes were calculated and expressed as
% of the sham group by dividing their volumes to the overall average sham volume.

Western Blotting
Fibronectin and vitronectin expressions were quantified by Western blot at 28
days post-GMH (n=5/group). Briefly, whole brain samples were processed according to
previously published protocols (Ma, Huang et al. 2011), and equal amounts of protein (50
µg) were separated by SDS-PAGE before being transferred onto nitrocellulose
membranes. The latter were then blocked and incubated with the following primary
antibodies: anti-fibronectin, anti-vitronectin (1:1000; Abcam) and anti-β-actin (1:4000;
Santa Cruz Biotechnology, Santa Cruz, CA). After incubation with the primary and the
appropriate secondary antibodies (1:4000; Santa Cruz Biotechnology, Santa Cruz, CA),
immunoblots were visualized with the ECL Plus chemiluminescence reagent kit
(Amersham Bioscience, Arlington Heights, IL) and bands were quantified using Image J
(NIH). Results, expressed as mean±SEM, were normalized to the average values of the
sham group.

Statistical Analysis
Sample size estimations were made by power analysis using a type I error rate of
0.05 and a power of 0.8 on a two-sided test. Data are expressed as meanSEM. Western
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blot and histological data were analyzed by one-way ANOVA followed by the Tukey
post-hoc test, and behavior data were analyzed by one-way ANOVA on ranks and the
Student-Newman-Keuls method. A P value <0.05 was considered statistically
significant.

Results
Deferoxamine Improved Brain Morphology after GMH
At 28 days post-GMH, brain morphology was assessed in Nissl stained brain
sections (n=5 group). Ventricular volume was found significantly increased in the
vehicle group compared to sham, but acute and delayed Deferoxamine treatment
significantly reduced GMH-induced ventricular dilation (P<0.05; Figure 3.1.A). Cortical
thickness was evaluated as a right hemisphere/left hemisphere ratio to the mean of sham
and was significantly decreased in the vehicle group compared to sham-operated animals,
but acute and delayed Deferoxamine treatment ameliorated cortical loss (P<0.05, Figure
3.1.B). Basal ganglia volume was evaluated as a percentage to mean sham basal ganglia
volume (Figure 3.1.C). Acute and delayed Deferoxamine treated groups had significantly
less basal ganglia loss compared to the vehicle group (P<0.05; Figure 3.1.C). White
matter loss was evaluated as a percent loss using sham-operated animals as a baseline
(Figure 3.1.D). Acute and delayed Deferoxamine treated groups had significantly less
white matter loss compared to the vehicle group (P<0.05; Figure 3.1.D).
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Figure 3.1: Long-term brain morphological outcomes after acute and delayed
Deferoxamine treatment at 4 weeks post-GMH. Quantification of (A) ventricular
volume, (B) cortical thickness, (C) basal ganglia loss, and (D) white matter loss at 28
days after germinal matrix hemorrhage. Values are expressed as meanSEM. *P<0.05
compared to sham, and #P<0.05 compared to vehicle. N=5 per group.
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Deferoxamine Reduced Extracellular Matrix Protein Expression after GMH
Western blot analyses were conducted at 28 days post-GMH induction (n=5 per
group). Fibronectin expression was found increased in the vehicle group compared to
sham-operated animals, and acute and delayed Deferoxamine treatment significantly
reduced fibronectin expression after GMH (P<0.05; Figure 3.2.A). Vitronectin
expression was also significantly increased in the vehicle group compared to shamoperated animals, and acute and delayed Deferoxamine treatment tended to reduce
vitronectin expression after GMH (P>0.05 vs sham; Figure 3.2.B).
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Figure 3.2: Extracellular matrix protein expression levels after acute and delayed
Deferoxamine treatment at 4 weeks post-GMH. Western blot analysis of (A)
Fibronectin and (B) Vitronectin at 28 days after germinal matrix hemorrhage.
Representative microphotographs of Nissl stained brain sections (C) at 28 days after
germinal matrix hemorrhage. Values are expressed as meanSEM. *P<0.05 compared
to sham, and #P<0.05 compared to vehicle. N=5 per group.
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Deferoxamine Improved Long-term Neurofunctional Outcomes after GMH
Vehicle treated GMH animals demonstrated significant spatial memory loss
compared to sham-operated animals in the Morris water maze by swimming greater
distances finding the platform (P<0.05; Figure 3.3.A) and spending less time in the target
quadrant during the probe trials (P<0.05; Figure 3.3.B). Acute and delayed treatment
animals showed significant cognitive functional recovery by having reduced swimming
distances (P<0.05; Figure 3.3.A) and tended to spend more time in the target quadrant
during the probe trials (P>0.05 vs sham; Figure 3.3.B). Furthermore, vehicle animals had
significantly more foot faults than sham, but acute and delayed Deferoxamine treated
GMH animals had significantly reduced foot faults compared to vehicle (P<0.05; Figure
3.3.C). Vehicle animals had significantly worse rotarod performances compared to sham,
but acute and delayed Deferoxamine treated animals had significantly better rotarod
performances than vehicle rats (P<0.05; Figure 3.3.D).
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Figure 3.3: Long-term neurocognitive and sensorimotore recovery after acute and
delayed Deferoxamine treatment at 3-4 weeks post-GMH. Neurofunctional
assessment of (A) & (B) Morris water maze, (C) rotarod, and (D) foot fault test at 21-28
days after germinal matrix hemorrhage. Values are expressed as meanSEM. *P<0.05
compared to sham, and #P<0.05 compared to vehicle. N=10 per group.
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Discussion
Iron toxicity is known to play a crucial pathophysiological role in brain injury
following hemorrhage, with some evidence indicating iron overload may contribute to
hydrocephalus development (Lee, Keep et al. 2010; Chen, Gao et al. 2011; Xiong, Wang
et al. 2013). Blood products and extracellular matrix protein proliferation are thought to
significantly contribute to post-hemorrhagic hydrocephalus development by disrupting
normal cerebrospinal fluid flow in the ventricles (Crews, Wyss-Coray et al. 2004).
Deferoxamine treatment attenuated brain injury in adult brain hemorrhage models (Lee,
Keep et al. 2011; Hatakeyama, Okauchi et al. 2013), yet it has not been evaluated in
neonates nor has it been shown to significantly attenuate neonatal post-hemorrhagic
hydrocephalus development and long-term neurofunctional deficits. This study evaluated
the efficacy of 1 hour (acute) and 72 hour (delayed) Deferoxamine treatment as a
potential therapeutic modality for GMH-induced brain injury, the delayed time point
serving as a more clinically relevant treatment regimen. Extracellular matrix protein
proliferation is indicative of gliosis and is hypothesized to deposit within the ventricles,
disrupting cerebrospinal fluid flow and contributing to post-hemorrhagic hydrocephalus
development. Fibronectin and vitronectin were significantly increased in GMH animals
compared to sham-operated animals, yet acute and delayed Deferoxamine treated animals
had significantly reduced fibronectin and vitronectin expressions compared to vehicle,
indicating GMH leads to increased extracellular matrix protein proliferation, which was
attenuated by iron chelation.
Additionally, vehicle treated GMH animals demonstrated significantly enlarged
ventricular volume, decreased cortical thickness, increased basal ganglia loss, and
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increased white matter loss, while acute and delayed Deferoxamine treated animals
showed significantly improved brain morphological outcomes across all measures.
Consequently, acute and delayed Deferoxamine treated GMH animals had significantly
improved spatial memory and motor coordination compared to vehicle animals. Our
results corroborate with similar brain hemorrhage animal models depicting Deferoxamine
treatment ameliorates post-hemorrhage brain injury. Furthermore, acute and delayed
post-GMH iron chelation significantly reduced neonatal post-hemorrhagic ventricular
dilation.
Our results suggest that iron toxicity at acute and delayed time points following
GMH is associated with post-hemorrhagic ventricular dilation, but the pathophysiological
mechanisms remain to be elucidated. The choroid plexus is an epithelial layer in the
ventricles specialized for cerebrospinal fluid production and is susceptible to injury
following hemorrhage (Simard, Tosun et al. 2011). It also contains high expression
levels of iron metabolic proteins relative to other brain tissues (Rouault, Zhang et al.
2009). Iron-overload in the cerebroventricular system following GMH may adversely
affect normal functioning of the choroid plexus, leading to pathologically increased
cerebrospinal fluid production. Another possible explanation is GMH-induced
cerebroventricular iron overload destroys subarachnoid granulations, as is observed in
subarachnoid hemorrhage, reducing overall cerebrospinal fluid reabsorption (Okubo,
Strahle et al. 2013). Further investigations are needed to determine mechanisms linking
GMH-induced iron toxicity with long-term post-hemorrhagic ventricular dilation.
Our study is the first to show Deferoxamine attenuates long-term neurocognitive
and sensorimotor deficits, improves overall brain morphology, and reduces post-
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hemorrhagic ventricular dilation following GMH when treatment is initiated as late as 72
hours post-ictus in neonates, providing evidence for a potentially clinically translatable
therapeutic modality.
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Abstract
This study examines the role of thrombin’s protease-activated receptors (PAR)-1,
PAR-4 in mediating cyclooxygenase-2 and mammalian target of rapamycin following
germinal matrix hemorrhage. Germinal matrix hemorrhage was induced by
intraparenchymal infusion of bacterial collagenase into the right ganglionic eminence of
P7 rat pups. Animals were treated with either PAR-1, PAR-4, cyclooxygenase-2, or
mammalian target of rapamycin inhibitors by 1 hour and up to ≤5 days. We found
increased thrombin activity 6 to24 hours after germinal matrix hemorrhage,, and PAR-1,
PAR-4 inhibition normalized cyclooxygenase-2 and mammalian target of rapamycin by
72 hours. Early treatment with NS398 or rapamycin substantially improved long-term
outcomes in juvenile animals. Suppressing early PAR signal transduction, and postnatal
NS398 or rapamycin treatment, may help reduce germinal matrix hemorrhage severity in
susceptible preterm infants.
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Introduction
Germinal matrix hemorrhage (GMH) is the leading cause of mortality and
morbidity from prematurity because this brain region is selectively vulnerable to
spontaneous bleeding within the first 72 hours of preterm life (Ballabh 2010).
Cerebroventricular expansion contributes to long-term injury through mechanical
compression of surrounding brain tissues (Aquilina, Chakkarapani et al. 2011).
Neurological outcomes include hydrocephalus, mental retardation, and cerebral palsy
(Ballabh 2010; Heron, Sutton et al. 2010). Current neonatal intensive care treatments are
ineffective at preventing GMH, and neurosurgical shunts are prone to devastating
complications (Whitelaw 2001).
Importantly, the blood constituent thrombin has been identified as a causative
factor in hydrocephalus formation (Gao, Liu et al. 2014). Thrombin activates a subfamily
of G protein-coupled receptors, named proteinase-activated receptors (PAR; specifically
PAR-1 and PAR-4) (Kataoka, Hamilton et al. 2003), leading to phosphorylation and
activation of mammalian target of rapamycin (mTOR) (Jiang, Zhu et al. 2008) and
increased cyclooxygenase (COX)-2 expression (Lo, Chen et al. 2009).
Therefore, we hypothesized that modulation of the thrombin- (PAR)-1,-4 –
(COX)-2/ mTOR pathway could be a promising strategy to improve outcomes after
GMH.

Materials and Methods
Animal Surgeries
All studies, protocols, and procedures were approved by the Loma Linda
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University IACUC. One hundred and fifty-seven P7 rat pups (comparable with human
30-32 gestational weeks (Lekic, Manaenko et al. 2012); 14–19 g; Harlan Laboratories,
Indianapolis, IN) were randomly subjected to either GMH or sham operations. The
number of pups needed for the experiments and study mechanisms was accounted for in
each test group. The sample size estimates for all groups assumed type 1 error rate = 0.05
and power = 0.8 on a two-sided test. Sample size estimates were then made using data
from our previous experiments (per previous assumptions, mean values, standard
deviation, and up to a 20% change in means). A stereotactically guided, 0.3 U bacterial
collagenase infusion model was used to mimic preterm right-sided ganglionic eminence
bleeds (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al.
2014) (except for the cohort using either heat-deactivated collagenase, 30µl of donor
blood, or corresponding amount of thrombin [5U], directly injected into the ventricles to
study hydrocephalus). Time pregnant rats were purchased from Harlan Laboratories
(Indianapolis, IN) and pups of both genders were subjected to spontaneous germinal
matrix hemorrhage (GMH) using collagenase infusion (Lekic, Manaenko et al. 2012).
Briefly, general anesthesia was achieved by isoflurane (3% in 30/70% Oxygen/Medical
Air). The anesthetized rat pup was positioned prone, with its head secured onto a neonatal
stereotactic frame (Kopf Instruments, Tujunga, CA). Next, the scalp was sterilized (using
betadine solution), and a small midline incision was made to expose the bregma. Then, a
1 mm cranial burr hole was made using a standard dental drill (coordinates from bregma:
1.8 mm anterior, 1.5 mm lateral, 2.8 mm in depth) through which a 26-gauge needle was
stereotaxically lowered into the rodent’s brain. At this position, clostridial collagenase
VII-S (0.3 U, Sigma; St. Louis, MO) was infused at a rate of 0.25μl/min into the right
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striatum. The needle was left in place for 10 minutes following infusion completion to
prevent backflow of collagenase. Thereafter, the needle was slowly withdrawn at a rate of
1mm/min; the burr hole was sealed with bone wax; and the scalp was sutured closed. All
animals were allowed to recover under observation on a 37°C warm heating blanket
before being returned to their dams. Shams received needle insertion only without
collagenase infusion.

Tissue Processing and Analysis
Rats were euthanized at 72 hours (for Western blot) at various time points
between 6 hrs and 21 days (for thrombin assay), and after 28 days (for neuropathological
analysis) post-GMH, and analyzed by blinded experts (Lekic, Manaenko et al. 2012;
Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014). Standard protocols (Lekic,
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014) were
used for Western blot analysis at 72 hours post-GMH. Briefly, deeply anesthetized pups
were transcardially perfused using 50ml PBS, and the whole brain tissue samples were
collected. Both hemispheres (i.e. bilateral forebrain) were placed into a single test tube
for further analysis. Following tissue preparation and protein extractions of the bilateral
hemispheres, western blotting was performed using the following primary antibodies:
anti-COX-2 (1:200; Cayman Chemical, Ann Arbor, MI), or anti-phospho-mTOR
(1:1000; Cell Signaling Technology, Danvers, MA). The appropriate secondary
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunoblots were visualized using ECL Plus chemiluminescence kit (Amersham
Bioscience, Arlington Heights, IL) and further semi-quantitatively analyzed using Image
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J (4.0, Media Cybernetics, Silver Springs, MD). Results are expressed as a relative
density ratio, adjusted to sham.
Standard protocols (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013;
Manaenko, Lekic et al. 2014) were used for Thrombin assay. Briefly, animals were
transcardially perfused with phosphate-buffered saline at 6 hours, 1 day, 5 days, 7 days,
10 days, and 21 days after GMH. Brain samples were then homogenized and thrombin
activity was measured using the thrombin-specific chromogenic substrate, S2238
(Anaspec, Fremont, CA) as previously described (Gong, Xi et al. 2008). The final
concentration of the s2238 solution was 20mM in phosphate-buffered saline. Thrombin
standards were made using rat thrombin (Sigma Aldrich, St. Louis, MO) at
concentrations of 0, 1.5625, 3.125, 6.25, 12.5, 25, and 50 mU/ml. Reaction mixtures
consisted of 10 µl of brain sample supernatant and 1.5ul of the s2238 chromogenic
substrate mixture, which were then added to 90 µl of phosphate-buffered saline.
Reaction mixtures were allowed to incubate for 1hr at room temperature, after which the
sample absorbance were spectrophotometrically measured at 405 nm.
Standard protocols (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013;
Manaenko, Lekic et al. 2014) were used for histopathological analysis at 28 days postGMH. Briefly, deeply anesthetized pups were transcardially perfused using 50 ml icecold PBS and 10% paraformaldehyde. Whole brain tissue samples were post-fixed in
10% paraformaldehyde solution (at 4°C for 3 days), then dehydrated in 30% sucrose for
the same amount of time. 10 μm frozen coronal brain sections were cut every 600 μm
using the cryostat (CM3050S, Leica Microsystems), then mounted, and cresyl violet
stained on poly-L-lysine-coated slides. Morphometric analysis was conducted using
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computer-assisted (ImageJ 4.0, Media Cybernetics, Silver Spring, MD) hand delineation
of the ventricle system (lateral, third, cerebral aqueduct, and fourth), hemisphere (cortex,
subcortex), corpus callosum (white matter), caudate, thalamus, and hippocampus.
Borderlines of these structures are based on criteria derived from stereologic studies
using optical dissector principles (Oorschot 1996; Ekinci, Acer et al. 2008; Lekic,
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014).
Volumes were calculated: (Average [(Area of coronal section) × Interval × Number of
sections]).

Animal Treatments and Experimental Groups
For the 72-hour (short-term; n=49) western blot study: GMH animals received i.p.
co-injections of PAR-1 (SCH79797) and PAR-4 (P4pal-10) antagonists (1, 3, 7, 10, or 15
mg/kg given 1, 24, and 48 hrs post-GMH). For thrombin assay time-course study (n=49,
n=7/per time point); GMH animals were euthanized at 0 hour, 6 hours, 1 day, 5 days, 7
days, 10 days, and 21 days after GMH. For the 28-day (long-term; n=26) study, COX-2
(NS398) or mTOR (rapamycin) treatment consisted of six intraperitoneal. injections (1, 6,
24, 36, 48, and 60 hours after GMH). Inhibitors were prepared using distilled water
containing five percent Dimethyl Sulfoxide (DMSO) solvent. Controls received the
vehicle (5% DMSO). All drugs were purchased from Sigma-Aldrich (St. Louis, MO).10-11

Assessment of Neurological Deficits
Cognitive (T-maze, Water-maze) and sensorimotor (Rotarod, Foot Fault) testing
from 21 to 28 days post-GMH was performed by experienced blinded investigators as
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described (Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014). Briefly, the TMaze1-2 assessed short-term (working) memory ability. For each trial, the pup was
placed into the stem (40cm×10cm) and allowed to explore until either the left or right
arm was chosen. From the sequence of 10 trials, the rate of spontaneous alternation (0%
= none and 100% = complete; alternations/trial) was calculated. The Morris Water-maze
(Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014)
measured spatial learning and memory on three daily blocks. The apparatus consists of a
metal pool (110cm diameter) filled with water to within 15cm of the upper edge and
containing a small platform (11cm diameter) for the animal to climb onto. The swim
path length was digitally analyzed by Noldus Ethovision tracking software. Cued trials
(maximum of 60 sec/trial) measured general associative learning, sensorimotor ability,
and motivation to escape the water with the platform visible above the water surface. The
platform’s location changed every other trial. Spatial trials (maximum of 60 sec/trial)
measured spatial learning with the platform submerged, but discoverable. Probe trials
measured spatial memory by recording the amount of time in the target quadrant after the
escape platform was removed. For the rotarod (Lekic, Manaenko et al. 2012; Leitzke,
Rolland et al. 2013), this test assessed motor and coordination ability. The apparatus
(Columbus Instruments, Columbus, OH) consists of a horizontally rotating cylinder
requiring continuous walking in order to avoid falling (7 cm diameter, 9.5 cm width) and
programmed to either maintain a constant velocity, or to accelerate 2 rpm every 5 sec.
The time to fall was recorded by photobeam circuit. For Foot Fault testing (Lekic,
Manaenko et al. 2012; Manaenko, Lekic et al. 2014), this documented the number of
completed limb missteps through the openings while the animal explored an elevated
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wire (3mm) grid (20cmx100cm) over 120sec. All neurobehavior assessments were
conducted in a blinded fashion by experienced investigators.

Statistical Analysis
P values of <0.05 were considered statistically significant. Neurobehavioral data
were analyzed using one-way ANOVA on ranks with Student–Newman–Keuls post-hoc
test. All other data were analyzed by one-way ANOVA with Tukey post-hoc test. Data
are expressed as mean±SEM.

Results
GMH Activated Thrombin
Thrombin activity increased at 6 and 24 hours following collagenase infusion
compared to sham (P<0.05), and then normalized over 5 to 21 days (Figure 4.1.B).

Molecular Mediators of Post-hemorrhagic Hydrocephalus
Post-hemorrhagic hydrocephalus at 28 days was greatest in the group receiving
direct intraparenchymal infusion of collagenase into the ganglionic eminence (P<0.05;
Figure 4.1.C-D) compared with intracerebroventricular injections of collagenase, heatdeactivated collagenase, donor blood, or thrombin.
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Figure 4.1: Thrombin activity after germinal matrix hemorrhage and association
between specific GMH model elements and post-hemorrhagic ventricular dilation
development. (A) Proposed mechanism. (B) Time-course of thrombin activity
(n=7/group; * P<0.05 compared with sham). (C) Representative 2mm coronal brain
section pictographs (28 days after infusion). (D) Quantification of ventricular volume
(n=6/group; * P<0.05 compared with vehicle). ICV indicates intracerebroventricular;
RAPA, rapamycin.
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Western Blots
Early PAR-1 and PAR-4 signal inhibition reduced mTOR phosphorylation and
COX-2 expression (P<0.05; Figure 4.2A-B) in a dose responsive fashion at 72 hours
post-GMH induction.
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Figure 4.2: Dose-response changes of COX-2 and p-mTOR expression after
combinatorial PAR-1 and PAR-4 inhibition at 72 hours post-GMH as well as longterm brain morphological outcomes after COX-2 or mTOR inhibition at 4 weeks
post-GMH. (A- B) Western blot analyses of p-mTOR (left) and COX-2 expression
(right) at 72 hours after GMH (n=7/group). (C) Representative Nissl stained brain
micrograph sections (left), quantification of cortical thickness (right) and (D) ventricular
volume at 28 days after GMH. * P<0.05 compared with sham; ϯ P<0.05 compared with
vehicle.
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Early Signal Inhibition Improved Long-term Outcomes
Treatments using either COX-2 or mTOR inhibitors significantly ameliorated
long-term cortical thickness, ventricular volume (P<0.05; Figures 4.2.C-D), and
neurodeficits (Figure 4.3.A-D) compared to vehicle treated animals at 28 days postGMH.
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Figure 4.3: Long-term neurocognitive and sensorimotor outcomes after COX-2 or
mTOR inhibition at 3-4 weeks post-GMH. Neurological assessments at 21-28 days
after GMH using A. Morris water maze, B. T-maze, C. Foot fault, and D. Rotarod test
(n=5-7/group). * P<0.05 compared with sham; ϯ P<0.05 compared with vehicle.
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Discussion
This study investigated the effectiveness of modulating thrombin- PAR-1 and
PAR-4 in reversing COX-2 and p-mTOR upregulation, as well as the effect of direct
COX-2 and p-mTOR inhibition upon post-hemorrhagic hydrocephalus and neurological
deficits. Previous studies hypothesized the mechanism of hydrocephalus involved
increased production of infiltrating extracellular matrix proteins throughout the
cerebroventricular system, leading to the disruption of CSF outflow (Crews, Wyss-Coray
et al. 2004; Ballabh 2010; Aquilina, Chakkarapani et al. 2011; Strahle, Garton et al. 2012;
Manaenko, Lekic et al. 2014). Our results suggest that thrombin-induced PAR-1, PAR-4
stimulation upregulates detrimental signaling: exacerbating inflammatory (COX-2
mediated) and proliferative responses (p-mTOR mediated) that are potentially upstream
of extracellular matrix protein dysregulation (Jiang, Zhu et al. 2008; Lo, Chen et al. 2009;
Ballabh 2010; Lekic, Manaenko et al. 2012; Gao, Du et al. 2014; Gao, Liu et al. 2014;
Manaenko, Lekic et al. 2014).Multiple parallels (especially with thrombin) (Jiang, Zhu et
al. 2008; Lo, Chen et al. 2009; Ballabh 2010; Aquilina, Chakkarapani et al. 2011; Lekic,
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014) exist
between our study and the pathophysiology of adult intracerebral hemorrhage (Whitelaw
2001; Crews, Wyss-Coray et al. 2004; Strahle, Garton et al. 2012; Gao, Du et al. 2014;
Gao, Liu et al. 2014). Thus, in extension, our findings may have a much broader
therapeutic implication in terms of further adult stroke mechanistic study (Keep, Zhou et
al. 2014).
To address the question of molecular mediators of GMH, our first aim
demonstrated that intraparenchymal infusion of collagenase generated the majority of
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hydrocephalus. This is likely the sum contribution of blood products (Gao, Du et al.
2014) (red blood cell lysis and inflammation) and thrombin. In fact, thrombin
demonstrated greatest activity in the acute phase, between 6 and 24 hours post-ictus, with
tendency to remain elevated ≤10 days and normalized by 21 days.
We next hypothesized that thrombin binds to PAR-1, PAR-4 receptors, and
consequently upregulates COX-2 and p-mTOR. Because thrombin is most active in the
acute phase, we examined levels at 72 hours post-ictus and determined COX-2 and pmTOR were significantly greater in vehicle treated animals than in sham. Furthermore,
inhibiting PAR-1, PAR-4 using SCH79797 (PAR-1 antagonist) and p4pal10 (PAR-4
antagonist) significantly normalized COX-2 and p-mTOR levels at 72 hours.
Then, we asked whether directly inhibiting COX-2 or p-mTOR after GMH could
circumvent long-term post-hemorrhagic ventricular dilation, cortical cell loss, and
improve sensorimotor and neurocognitive outcomes. Our findings demonstrated that
vehicle treated animals had significantly worsened outcomes compared to shams, and
treating with either NS398 (COX-2 inhibitor) or rapamycin (mTOR inhibitor)
significantly improved brain neuropathology and neurological ability. Thus, by
attenuating early inflammatory (COX-2), and proliferative (p-mTOR) signaling
pathways, we improved long-term outcomes in the juvenile animals.
In summary, this study is the first to show thrombin-PAR-1, thrombin-PAR-4
signal inhibition normalizing early COX-2 and p-mTOR expression levels, and this, in
turn, improving long-term neurological outcomes after GMH.
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Abstract
We aim to determine if direct thrombin inhibition by Dabigatran will improve
long-term brain morphological and neurofunctional outcomes and if potential therapeutic
effects are dependent upon reduced PAR-1 stimulation and consequent mTOR activation.
Germinal matrix hemorrhage was induced by stereotaxically injecting 0.3 U type VII-S
collagenase into the germinal matrix of P7 rat pups. Animals were divided into 5 groups:
Sham, Vehicle (5% DMSO), Dabigatran intraperitoneal, Dabigatran intraperitoneal +
TFLLR-NH2 (PAR-1 agonist) intranasal, SCH79797 (PAR-1 antagonist) intraperitoneal,
and Dabigatran intranasal. Neurofunctional outcomes were determined by Morris water
maze, rotarod, and foot fault evaluations at 3 weeks. Brain morphological outcomes were
determined by histological Nissl staining at 4 weeks. Expression levels of p-mTOR/pp70s6k at 3 days and vitronectin/fibronectin at 28 days were quantified. Intranasal and
intraperitoneal Dabigatran promoted long-term neurofunctional recovery, improved brain
morphological outcomes, and reduced intracranial pressure at 4 weeks after GMH. PAR1 stimulation tended to reverse Dabigatran's effects on post-hemorrhagic hydrocephalus
development. Dabigatran also reduced expression of short-term p-mTOR and long-term
extracellular matrix proteins, which tended to be reversed by PAR-1 agonist coadministration. PAR-1 inhibition alone, however, did not achieve the same therapeutic
effects as Dabigatran administration. Direct thrombin inhibition ameliorated long-term
germinal matrix hemorrhage brain sequelae, which was associated with decreased shortterm mTOR activation. PAR-1 stimulation tended to reverse some therapeutic effects, but
PAR-1 inhibition alone was not sufficient to improve outcomes.
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Introduction
Occurring in approximately 3.5 per 1000 live births, germinal matrix hemorrhage
(GMH) remains a leading cause of mortality and lifelong morbidity in premature and/or
very low birthweight infants (Heron, Sutton et al. 2010). The rupturing of immature
blood vessels in the subependymal brain tissue is thought to result from deficient
autoregulatory mechanisms that inadequately function in response to abnormal cerebral
blood flow fluctuations spurred by cardiorespiratory and hemodynamic instability
(Ballabh 2014). Long-term clinical complications from GMH include developmental
delays, learning and psychiatric disorders, cerebral palsy, and post-hemorrhagic
hydrocephalus, all of which pose significant economic burdens on both the patients and
the US healthcare system (1993; Vohr, Wright et al. 2000; Murphy, Inder et al. 2002).
Prenatal glucocorticoid administration remains the best treatment for preventing GMH in
premature infants, yet few clinical approaches exist for GMH clinical management postictus (Leviton, Kuban et al. 1993; Vinukonda, Dummula et al. 2010). Minimal
advancements have also been made in post-hemorrhagic hydrocephalus clinical
management, which is mostly limited to surgical insertion of shunts that drain excess
cerebrospinal fluid from the ventricles into the peritoneum (Whitelaw 2001; Ballabh
2014). Thus, a non-invasive, safe therapeutic approach that successfully mitigates posthemorrhagic hydrocephalus development after GMH would significantly improve the
quality of life for this patient population.
Immediately after hemorrhage, the coagulation cascade is triggered and thrombin,
a serine protease, is activated (Babu, Bagley et al. 2012). In addition to inducing clot
formation by converting fibrinogen into fibrin, thrombin also stimulates proteinase-
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activated receptors (PARs) (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et al.
2005; Luo, Wang et al. 2007), leading to phosphorylation and subsequent activation of
mammalian target of rapamycin (mTOR) (Lekic, Klebe et al. 2015). Activated mTOR
has been associated with extracellular matrix (ECM) protein proliferation in fibroblasts,
which possibly disrupts CSF dynamics in the cerebroventricular system (Paul, Leef et al.
2000; Crews, Wyss-Coray et al. 2004; Del Bigio 2004; Xue and Del Bigio 2005; Ballabh,
Xu et al. 2007; Dummula, Vinukonda et al. 2010). In our prior studies, long-term postGMH ventricular dilation was associated with increased expression of vitronectin and
fibronectin (Klebe, Krafft et al. 2014), combinatorial PAR-1 and PAR-4 inhibitors
reduced p-mTOR expression at 72 hours after GMH, and rapamycin treatment
ameliorated long-term neurocognitive deficits and improved brain morphology at 4
weeks post-GMH (Lekic, Klebe et al. 2015). Yet, long-term evaluations for PAR-1
and/or PAR-4 inhibitor administration as well as ECM protein expression levels were not
investigated in these studies. Nonetheless, inhibiting the Thrombin/PAR/mTOR pathway
seems be a promising strategy for ameliorating post-hemorrhagic hydrocephalus
formation after GMH.
Dabigatran, an oral anti-coagulant also known as Pradaxa, is a direct thrombin
inhibitor clinically approved for preventing deep vein thrombosis, pulmonary embolism,
and stroke from atrial fibrillation (Eisert, Hauel et al. 2010; van Ryn, Stangier et al.
2010). While Dabigatran reduced overall major and minor bleeding events compared to
Warfarin, gastrointestinal bleeds were significantly higher (Blommel and Blommel
2011). An antidote, Idarucizumab, was developed to reverse Dabigatran’s anti-coagulant
effects in the event of major, uncontrolled bleeds (Starke, Komotar et al. 2015). Although
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inhibiting thrombin may ameliorate brain injury, Dabigatran’s anti-coagulant properties
pose a risk of increased bleeding after cerebral hemorrhage. Dabigatran was evaluated in
a rodent model of adult intracerebral hemorrhage and was determined to not increase
hematoma volume while attenuating brain injury for the doses evaluated (Lauer,
Cianchetti et al. 2011), but an additional study suggests high doses of Dabigatran do
increase hematoma volume, which can be controlled by intravenous injection of
prothrombin complex concentrate (Zhou, Schwarting et al. 2011). We perform a similar
dosing study to evaluate Dabigatran’s safety for GMH and to determine the best dose for
further investigation.
Herein, we evaluate if direct thrombin inhibition by Dabigatran ameliorates longterm neurocognitive deficits, improves brain morphological outcomes, and reduces ECM
proliferation. We further investigate if potential therapeutic effects are dependent upon
reduced PAR-1 stimulation and subsequent mTOR activation, since PAR-1 inhibition
reduced brain injury severity in both adult cerebral ischemic and hemorrhage models.
Given Dabigatran’s anti-coagulant effects, inhibiting one of thrombin’s receptors may be
a safer approach if it still achieves the same degree of efficacy, and we aim to determine
if PAR-1 inhibition alone will potentially achieve the same therapeutic benefits as direct
thrombin inhibition. We further evaluate if PAR-1 stimulation will reverse Dabigatran’s
therapeutic effects to better confirm this pathway’s role in GMH pathophysiology.
Additionally, intranasal drug administration has been shown to be an effective, localized
delivery route to the brain and we aimed to determine if this route would be efficacious
for Dabigatran administration (McMartin, Hutchinson et al. 1987; Djupesland, Messina et
al. 2014). We determine the effects of the thrombin/PAR-1 pathway on mTOR
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phosphorylation in the short-term as well as ECM protein expression, brain morphology,
neurocognitive and sensorimotor function, and intracranial pressure in the long-term.

Materials and Methods
GMH Surgical Procedures
All procedures were approved by the Loma Linda University Institutional Animal
Care and Use Committee in accordance with the National Institute of Health’s guidelines.
For GMH induction, postnatal day 7 rat pups weighing between 12-15 grams (brain
development comparable to 30-32 week human gestation) were anesthetized using 2-3%
isoflurane delivered in a mixture of medical grade oxygen and air. The scalp was
sterilized by topically applying isopropyl alcohol and betadine, and then the heads were
fixed onto a stereotaxic frame. An incision was made to expose bregma and a 1 mm burr
hole was drilled at 1.6 mm right lateral and 1.5 mm rostral relative to bregma. A 10 µL
Hamilton syringe filled with 0.3 U/µL collagenase solution was fixed to an infusion
pump (Harvard Apparatus, Holliston, MA) and the needle inserted to a depth of 2.8 mm
below the dura with the bevel facing the midline. 0.3 U type VII-S collagenase from
Clostridium hystolyticum (Sigma Aldrich, St. Louis, MO) was infused at a rate of 0.1
U/min, and the needle was left in place for 5 minutes before being removed at a rate of 1
mm/min to reduce backflow. The burr hole was sealed using bone wax and the incision
sutured with 5-0 silk. Animals were allowed to recover on a 37ᵒC heating pad then
returned to the dam after awakening from anesthesia. Sham surgery involved needle
insertion without collagenase infusion. The average surgery time was approximately 30
minutes per animal.
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Experimental Groups and Treatments
For the Dabigatran plasma concentration studies, 72 P7 rat pups were randomly
divided into three treatment groups: low dose 3 mg/kg, medium dose 10 mg/kg, or high
dose 30 mg/kg administered intraperitoneally. Lyophilized Dabigatran (Boehringer
Ingelheim, Ingelheim am Rhein, Germany) was dissolved into a 5% dimethyl sulfoxide
(DMSO) solution (Sigma Aldrich, St. Louis, MO). Blood was collected by cardiac
puncture prior to euthanization at 2, 4, 8, 12, 18, or 24 hours after Dabigatran
administration for all three treatment groups (n=4/group/endpoint). For the hematoma
expansion safety study, 48 P7 rat pups were randomly divided into 8 groups (n=6/group):
Sham, Vehicle (5% DMSO), 3 mg/kg Dabigatran QD, 3 mg/kg Dabigatran BID, 10
mg/kg Dabigatran QD, 10 mg/kg Dabigatran BID, 30 mg/kg Dabigatran QD, and 30
mg/kg Dabigatran BID. Dabigatran was administered intraperitoneally for this study. For
long-term evaluations, 72 P7 rat pups were randomly divided into 6 groups (n=1012/group, split evenly between histology and Western blot/intracranial pressure): Sham,
Vehicle, 3 mg/kg Dabigatran intraperitoneally, 3 mg/kg Dabigatran intraperitoneally + 1
mg/kg TFLLR-NH2 (PAR-1 agonist) intranasally (Tocris, Minneapolis, MN), 10 mg/kg
SCH79797 (PAR-1 antagonist) intraperitoneally (Tocris, Minneapolis, MN), and 3 mg/kg
Dabigatran intranasally. All pups were randomized among treatment groups and all
treatments commenced 2 hours post-ictus and then twice a day for 3 days. For time
course Western blots, 48 P7 rat pups were randomly divided into 8 groups (n=6/group)
and euthanized at the indicated time point after GMH: Naïve, 3, 6, 12 hours, 1 3, 5, and 7
days post-ictus. For short-term evaluations, 48 P7 rat pups were randomly divided into 8
groups (n=6/group): Sham, Vehicle BID for 3 days, 3 mg/kg Dabigatran
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intraperitoneally; 3 mg/kg Dabigatran intraperitoneally + 1 mg/kg TFLLR-NH2
intranasally; 10 mg/kg SCH79797 intraperitoneally; 3 mg/kg Dabigatran intranasally; 3
mg/kg Dabigatran intranasally + 1 mg/kg TFLLR-NH2 intranasally. The TFLLR-NH2
intranasal dose was derived from a prior in vivo rodent study (Aerts, Hamelin et al. 2013),
and the SCH79797 intraperitoneal dose was derived from our prior GMH study (Lekic,
Klebe et al. 2015).

Intracranial Pressure Measurement
Intracranial pressure was measured as previously described (Lackner, Vahmjanin
et al. 2013). At 28 days post-ictus, animals were anesthetized and mounted onto a
stereotaxic frame with their heads inclined 30ᵒ downward. The atlanto-occipital
membrane was exposed by a midline skin excision and the cisterna magna punctured
with a 26G needle connected to a pressure transducer (Digi-Med LPA 400, Micro-Med,
Louisville, KY).

Neurobehavioral Assessments
A battery of tests was performed, by blinded investigators, to evaluate
sensorimotor and cognitive deficits between 21-28 days post-ictus, as previously
performed (Klebe, Krafft et al. 2014; Flores, Klebe et al. 2016). Foot Fault Test: Rats
were placed on a wire grid (20x40 cm) 2 feet above the ground and allowed to walk for 2
minutes. The left limb faults are reported as a percentage of the total steps taken by the
left limbs ((left faults/left steps) x 100). Rotarod: Rats were placed on a rotating cylinder
(San Diego Instruments, Columbus, OH), 7 cm diameter, 9.6 cm lanes) accelerating at 2
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RPM per 5 seconds (starting speeds of either 5 or 10 RPM), and a photobeam circuit
detected the latency to fall off the cylinder. Morris Water Maze: Briefly, rats were trained
using a visible platform (10 cm diameter, Cued test) on day 1. Days 2-5, latency to find a
submerged platform was measured (Memory Blocks 1-4, 5 trials each block, 1 minute
each trial). After completing the memory test, the platform was removed and the rats
were tested to determine the amount of time spent within the platform quadrant (Probe
Trial, 1 minute trial). An overhead camera with a computerized tracking system (Noldus
Ethovision, Tacoma, WA) recorded the swim path and measured swim distance, speed,
and time spent in target quadrant.

Perfusions and Tissue Extraction
Deeply anesthetized (5% isoflurane) animals were euthanized by trans-cardiac
perfusion with ice-cold phosphate buffered saline (PBS) for hemoglobin assay and
Western blot samples or with ice-cold PBS followed by 10% formalin for histology
samples. Forebrains were either snap-frozen in liquid nitrogen and stored in -80ᵒC freezer
for Western blot and hemoglobin assay or post-fixed in 10% formaldehyde for at least 3
days then dehydrated with 30% sucrose for at least 3 days (4ᵒC) for histology. Histology
forebrains were embedded in Optimal Cutting Temperature compound and stored at 20ᵒC.

Hemoclot Assay
Blood was drawn by cardiac puncture and collected in a 0.106 mol/L trisodium
citrate solution (1 part anti-coagulant to 9 parts blood). Blood was centrifuged at 2600g
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for 10 minutes at 20ᵒC. Platelet poor plasma was collected and snap-frozen in liquid
nitrogen then stored at -80ᵒC until analysis. Dabigatran plasma concentration was
determined by Hemoclot Assay (Aniara, West Chester, OH) as previously
described.(Stangier and Feuring 2012) Briefly, a calibration curve was created using
control plasma with 0, 1.25, 2.5, 3.75, and 5 µg/mL Dabigatran. The Hemoclot Assay
was performed following the manufacturer guidelines Absorbance was measured on a
microplate spectrophotometer (iMark, Bio-Rad, Hercules, CA) at 405 nm against a blank.

Hemoglobin Assay
Frozen forebrains were homogenized in 3 mL PBS for at least 60 seconds then
sonicated for at least 60 seconds. The homogenate was centrifuged at 13000 RPM, 20ᵒC
for 30 minutes. 200 µL supernatant was combined with 800 µL Drabkin’s reagent
(Sigma-Aldrich, St. Louis, MO). After 15 minutes, absorbance at 450 nm was measured
using a spectrophotometer (Genesis 10 UV; Thermo Fisher Scientific, Waltham, MA).
Hemorrhage volume was calculated against a standard curve (created using naïve
forebrains and known quantities of blood).

Western Blot
Forebrains were homogenized in RIPA lysis buffer (Santa Cruz Biotechnology,
Dallas, TX) for at least 60 seconds. The homogenate was centrifuged at 15000 RPM, 4ᵒC
for 20 minutes and supernatant collected, aliquoted, then stored at -80ᵒC. Protein
concentrations were determined by DC protein assay (Bio-Rad, Hercules, CA). 50 µg
protein per sample were loaded into wells of 10% gels, ran for 30 minutes at 50 V, then
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90 minutes at 125 V. Proteins were transferred onto a nitrocellulose membrane at 0.3 A
for 120 minutes (Bio-Rad, Hercules, CA). Primary antibodies were applied to the
membranes and incubated overnight at 4ᵒC: p-mTOR (1:1000; Cell Signaling
Technology, Danvers, MA); p-p70s6k (1:1000; Cell Signaling Technology, Danvers,
MA); mTOR (1:1000; Cell Signaling Technology, Danvers, MA); p70s6k (1:1000; Cell
Signaling Technology, Danvers, MA); vitronectin (1:1000; Abcam, Cambridge, MA);
and actin (1:1000 Santa Cruz Biotechnology, Dallas, TX). Membranes were washed then
incubated in secondary antibodies (1:2000; Santa Cruz Biotechnology, Dallas, TX) for 2
hours at 4ᵒC. Proteins were exposed onto radiography film after applying enhanced
chemiluminescent solution (GE Healthcare and Life Science, Piscataway, NJ) onto the
membranes. ImageJ software (Media Cybernetics, Silver Spring, MD) was used to
analyses relative density.

Histology
A cryostat (Leica Microsystems LM3050S, Wetzlar, Germany) was used to cut 10
µm thick coronal sections every 600 µm into the brain. Brain slices were Nissl stained
and morphometrically analyzed using ImageJ (Media Cybernetics, Silver Spring, MD)
assisted delineation of brain structures, as previously performed in our lab (Lekic,
Manaenko et al. 2012). Ventricle volume was calculated as average ventricular area
multiplied by the depth of the cerebroventricular system. White matter loss was
calculated as the average white matter area multiplied by depth of the cerebroventricular
system and expressed as % of the sham group by dividing volumes to the overall average
volume of the Sham group.
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Statistical Analysis
Data are expressed as mean  standard deviation. One-way ANOVA using the
Newman-Keuls post-hoc test was used to analyses all data. A p<0.05 was considered
statistically significant in all analyses except neurobehavior; a p<0.10 was considered
statistically significant for neurobehavioral analyses.

Results
Dabigatran Half-life and Hematoma Volume after GMH
A dosing study was performed to assess the safety and efficacy of Dabigatran.
Plasma concentrations reached maximum levels 2 hours after injection and have an
approximate half-life of 8-12 hours (Figure 5.1.A). 30 mg/kg Dabigatran administered
intraperitoneally QD or BID significantly increased hematoma volume 24 hours after
GMH. 10 mg/kg Dabigatran administered intraperitoneally QD or BID had no effect on
hematoma volume 24 hours after GMH. 3 mg/kg Dabigatran QD administered
intraperitoneally had no effect on hematoma volume while Dabigatran BID tended to
decrease hematoma volume (Figure 5.1.B). Excessive bleeding and mortality associated
with excessive bleeding, where uncoagulated blood was usually found at the
abdomen/intestine, intraperitoneal injection site, and/or surgical suture on the head, was
also observed in all groups, particularly the higher dose groups (between 0-33%
mortality, data not shown).
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Figure 5.1: Dabigatran dose response for hematoma volume 24 hours post-GMH
and plasma concentration time course. Time course of Dabigatran plasma
concentrations after intraperitoneal injection of either 3 mg/kg, 10 mg/kg, or 30 mg/kg
Dabigatran (A). Hematoma volumes 24 hours post-GMH (B). *P<0.05 vs Sham; #P<0.05
vs Vehicle.
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Thrombin Inhibition Improved Long-term Neurofunctional Recovery, which
Was Not Reversed by PAR-1 Stimulation; PAR-1 Inhibition Alone Was Not
Sufficient to Promote Recovery
Using the best-tolerated dose, 3 mg/kg Dabigatran administered intraperitoneally
BID, we evaluated its efficacy on promoting long-term neurofunctional recovery. After
observing the bleeding side effects, particularly bleeding near the injection sites, as well
as mortality data from systemic Dabigatran administration, we decided to investigate if a
localized intranasal administration would promote long-term recovery. Dabigatran
intranasal administration may increase brain concentration compared to intraperitoneal
administration and avoids repeated abdominal injections, which may cause the observed
bleeding, although the high bioavailability of small drugs after intranasal delivery may
make blood plasma concentrations similar to intraperitoneal delivery and have the same
bleeding risk (McMartin, Hutchinson et al. 1987). The vehicle group performed
significantly worse than sham in the foot fault (Figure 5.2.A), rotarod (Figure 5.2.B), and
Morris water maze tests (Figure 5.2.C-D). Dabigatran administered intraperitoneally
significantly improved performances on the foot fault and rotarod tests, but did not
improve performance in the Morris water maze test compared to vehicle. PAR-1 agonist,
TFLLR-NH2, did not reverse neurobehavioral outcomes from intraperitoneal Dabigatran.
PAR-1 antagonist, SCH79797, administration did not improve performances on the foot
fault or Morris water maze tests, and only tended to improve performance on the rotarod
test compared to vehicle. Intranasal Dabigatran did not improve performance on the foot
fault test, tended to improve performance on the rotarod test, and significantly improved
performance on the Morris water maze test compared to vehicle.
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Figure 5.2: Long-term neurobehavioral outcomes after thrombin or PAR-1
inhibition at 3-4 weeks post-GMH. assessment using the foot fault (A), rotarod (B), and
Morris water maze tests for swim distance (C) and percentage of time spent in platform
quadrant (D). *P<0.10 vs Sham; #P<0.10 vs Vehicle; $P<0.10 vs Dabigatran i.p.;
&P<0.10 vs Dabigatran i.n.; @P<0.10 vs SCH79797.
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Thrombin Inhibition Improved Long-term Brain Morphological Outcomes,
which Tended to be Reversed by PAR-1 Stimulation; PAR-1 Inhibition Alone
Was Not Sufficient to Promote Recovery
To determine treatment effects on long-term post-hemorrhagic hydrocephalus
outcomes, intracranial pressure was measured and brain morphological outcomes
determined by histological analysis at 4 weeks post-GMH (Figure 5.3). Dabigatran
administered either intraperitoneally or intranasally had significantly diminished posthemorrhagic ventricular dilation (Figure 5.3.B) and white matter loss (Figure 5.3.C)
compared to vehicle. PAR-1 agonist co-administration significantly reversed
intraperitoneal Dabigatran’s effect on reduced post-hemorrhagic ventricular dilation and
tended to reverse intraperitoneal Dabigatran’s effect on ameliorating white matter loss.
PAR-1 antagonist administration did not significantly diminish post-hemorrhagic
ventricular dilation or white matter loss compared to vehicle. Additionally, the vehicle
group had significantly increased intracranial pressure compared to sham, which was
prevented by Dabigatran (intraperitoneal and intranasal) but not PAR-1 antagonism
(Figure 3.D). PAR-1 agonist co-administration significantly reversed intraperitoneal
Dabiagatran’s effects on diminishing intracranial pressure.
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Figure 5.3: Long-term brain morphological outcomes after thrombin or PAR-1
inhibition at 4 weeks post-GMH. Long term brain morphological. Representative
photomicrographs (A), ventricular volumes (ratio to sham mean) (B), and white matter
loss (percentage to sham mean) (C). Intracranial pressure at 4 weeks post-GMH (D).
*P<.05 vs Sham; #P<.05 vs Vehicle; $P<.05 vs Dabigatran i.p.; &P<.05 vs Dabigatran
i.n..
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Short-term p-mTOR and Downstream p-p70s6k Expression Levels Are
Significantly Increased after GMH
Activated mTOR has been implicated as a potential downstream effector of
thrombin-induced PAR stimulation, leading to consequent ECM protein proliferation. We
evaluated the expression time course of p-mTOR (Figure 5.4.A) and its downstream
effector, p-p70s6k (Figure 5.4.B), after GMH. Activated mTOR (p-mTOR) expression
levels were significantly increased 3 hours, and remained elevated up to 7 days postictus. Activated p70s6k (p-p70s6k) expression levels were significantly increased 3
hours, and remained increased at 3 days post-ictus, before returning to levels
indistinguishable from that of sham at 5 days post-ictus.
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Figure 5.4: Time course of mTOR/p70s6k activation after GMH. Time course of pmTOR (A) and p-p70s6k (B) protein expression in the brain after GMH. *P<.05 vs
Sham.
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Thrombin Inhibition Reduced p-mTOR and p-p70s5k Expression Levels at 3
Days Post-ictus, which Were Reversed by PAR-1 Stimulation; PAR-1 Inhibition
Alone Did Not Significantly Reduce p-mTOR and p-p70s6k Expression
Three days post-GMH, the effect of treatment on p-mTOR expression was
evaluated (Figure 5.5). Dabigatran (intraperitoneal and intranasal) significantly decreased
p-mTOR and p-p70s6k expression levels compared to vehicle, which were reversed by
PAR-1 agonist co-administration. Intraperitoneal PAR-1 antagonist administration did
not significantly reduce p-mTOR or p-p70s6k expression levels compared to vehicle
(Figure 5.5.A-B).
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Figure 5.5: Expression of activated mTOR/p70s6k after thrombin inhibition and
PAR-1 stimulation at 72 hours after GMH. Expression of p-mTOR and p-p70s6k
protein expression in the brain at 3 days post-GMH in rats treated with Dabigatran
administered intraperitoneally (A-B) or intranasally (C-D). *P<.05 vs Sham; #P<.05 vs
Vehicle; $P<.05 vs Dabigatran i.p.; &P<.05 vs Dabigatran i.n..
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Thrombin Inhibition Significantly Reduced Long-term ECM Protein
Proliferation after GMH, which Was Not Reversed by PAR-1 Stimulation;
PAR-1 Inhibition Alone Tended to Reduce ECM Protein Proliferation
ECM protein proliferation has been associated with post-hemorrhagic
hydrocephalus after GMH, thus we evaluated treatment effects on vitronectin (Figure
5.6.A) and fibronectin (Figure 5.6.B) expression levels 4 weeks post-ictus. The vehicle
group had significantly increased expression of both vitronectin and fibronectin
compared to sham, which was prevented by Dabigatran (intraperitoneal and intranasal)
and tended to decrease by PAR-1 antagonism. PAR-1 agonist co-administration did not
significantly reverse intraperitoneal Dabigatran effects on reducing vitronectin expression
and only tended to reverse intraperitoneal Dabigatran effects on reducing fibronectin
expression.
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Figure 5.6: Long-term expression of extracellular matrix proteins after thrombin
and PAR-1 inhibition at 4 weeks post-GMH. Expression of vitronectin (A) and
fibronectin (B) proteins in the brain at 4 weeks post-GMH. *P<.05 vs Sham; #P<.05 vs
Vehicle.
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Discussion
Post-hemorrhagic hydrocephalus is a common neurological sequelae afflicting
severe grade GMH patients, and a non-invasive therapeutic approach would significantly
improve the quality of life for this patient population. Elucidating clinically translatable
pathophysiological mechanisms contributing towards post-hemorrhagic hydrocephalus
development will hopefully yield novel therapeutic modalities to accomplish this aim.
Thrombin has been identified as a potentially critical player since intraventricular
thrombin injection results in brain tissue damage and ventricular dilation in adult rats,
which was reversed by intraventricular PAR-1 antagonist injection (Gao, Liu et al. 2014).
Thrombin activity is significantly upregulated 24 hours after GMH and tends to remain
elevated up to 10 days post-ictus (Lekic, Klebe et al. 2015). Additionally, stimulation of
thrombin’s receptors, protease-activated receptors-1, -3, and -4, upregulates downstream
proliferative pathways associated with brain injury, including PI3K/Akt, mTOR, and
MAPK (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et al. 2005; Luo, Wang et
al. 2007). Our prior studies determined active p-mTOR is significantly upregulated in
GMH rats at 72 hours post-ictus, and co-administration of PAR-1 and PAR-4 inhibitors
reduced p-mTOR expression levels. Additionally, mTOR inhibition by rapamycin
treatment improved long-term neurofunctional and brain morphological outcomes after
GMH (Lekic, Klebe et al. 2015). Thus, this pathway warrants further investigation.
Dabigatran is a novel direct thrombin inhibitor clinically approved for treating
deep vein thrombosis and preventing stroke from atrial fibrillation (Eisert, Hauel et al.
2010; van Ryn, Stangier et al. 2010). Similar to Argatroban (Chen 2001), Dabigatran is a
competitive inhibitor that reversibly binds to thrombin’s active site. We aimed to evaluate
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this clinically available drug in our neonatal rat GMH model. We first performed a
dosing study to 1) identify the half-life of Dabigatran, and 2) determine the best treatment
regimen to prevent hematoma expansion and other adverse effects. Plasma Dabigatran
concentrations after intraperitoneal administration was measured at 2, 4, 8, 12, 18, and 24
hours after injection using three doses: 3 mg/kg, 10 mg/kg, and 30 mg/kg. Plasma
concentrations for all three doses had peaked by 2 hours and the half-life was 8-12 hours
in neonatal rats (Figure 5.1.A).
While thrombin inhibition has yielded positive results in intracerebral hemorrhage
models, evidence suggests that high doses of thrombin inhibitors result in increased
hematoma volumes due to their anti-coagulant effects (Lauer, Cianchetti et al. 2011;
Zhou, Schwarting et al. 2011). Given Dabigatran’s 8-12 hour half-life, Dabigatran was
given QD and BID. Dabigatran (30 mg/kg) QD and BID resulted in significantly greater
hematoma volumes compared to that of the vehicle. Dabigatran (10 mg/kg) QD and BID
and Dabigatran (3 mg/kg) QD had hematoma volumes comparable to that of the vehicle,
whereas Dabigatran (3 mg/kg) BID tended to decrease hematoma volume (Figure 5.1.B).
We speculate Dabigatran’s anti-coagulant properties at 3 mg/kg are potent enough to
attenuate the accumulation of blood in the brain and cerebroventricular system while
preventing excess bleeding and consequent hematoma expansion. These findings are
analogous to studies investigating fibrinolytic agents to break down cerebroventricular
blood clots after intraventricular hemorrhage (Staykov, Huttner et al. 2009).
During the dosing study, some mortality was observed in the medium and high
dose groups, but many of the animals in those groups suffered from adverse bleeding
side-effects, particularly in the abdomen. We were concerned systemic administration of
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Dabigatran may be risky, so we decided to investigate if intranasal administration, which
is more localized to the brain, could be therapeutically beneficial, thus, an intranasal
administration group was added to the long-term study, and only 3 mg/kg Dabigatran
BID administered either intraperitoneally or intranasally was used, since it was best
tolerated. Recognizing that direct thrombin inhibitors have an inherent bleeding risk, we
investigated if 1) inhibiting PAR-1, a downstream thrombin receptor, will achieve the
same therapeutic results, and 2) stimulating PAR-1 will reverse Dabigatran’s therapeutic
effects.
Dabigatran treatment ameliorated long-term neurofunctional deficits.
Interestingly, intraperitoneal Dabigatran only improved locomotor and sensorimotor
outcomes, evidenced by better foot-fault and rotarod performances, while intranasal
Dabigatran administration only improved neurocognitive function, evidenced by better
Morris water maze performances (Figure 5.2). PAR-1 stimulation did not reverse
intraperitoneal Dabigatran’s therapeutic effects on foot-fault and rotarod performance,
and PAR-1 inhibition did not significantly attenuate any neurofunctional deficits,
although it tended to improve performance on the rotarod test. While both administration
routes had identical effects in every aspect of this study with neurobehavioral outcomes
being the only exception, these results may partially be explained by the inherent error
and variability within the tests, but the potential differential effects from the given
administration routes cannot be ignored. Regardless, both administration routes showed
significant neurofunctional recovery after GMH.
Both Dabigatran administration routes improved long-term brain morphological
outcomes by reducing post-hemorrhagic ventricular dilation and white matter loss
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compared to vehicle, and both routes reduced long-term intracranial pressure compared to
vehicle (Figure 5.3). PAR-1 stimulation showed a strong tendency to reverse
intraperitoneal Dabigatran’s therapeutic effects on brain morphological and intracranial
pressure outcomes since this group did not achieve a statistically significant difference
from the vehicle group. PAR-1 inhibition alone failed to ameliorate post-hemorrhagic
ventricular dilation, white matter loss, and elevated intracranial pressure. These results
suggest thrombin activity is associated with long-term post-hemorrhagic hydrocephalus
development, but post-hemorrhagic hydrocephalus development is not exclusively
dependent upon thrombin-induced PAR-1 stimulation, although it may play a minor role
in conjunction with other pathways. Indeed, activated thrombin also stimulates PAR-3
and PAR-4 as well, and their potential roles in GMH pathophysiology have not been
elucidated. PAR-1 inhibition alone also failed to ameliorate short-term subventricular
zone damage in a neonatal mouse GMH model (Mao and Del Bigio 2015), which is
consistent with our results showing PAR-1 inhibition failed to ameliorate long-term white
matter loss. Future investigations should rule out PAR-1 inhibition alone and focus on
PAR-3, PAR-4, or a combinatorial treatment approach.
Active thrombin is hypothesized to contribute towards fibrosis and consequent
ECM protein proliferation, which disrupt cerebrospinal fluid dynamics in the
cerebroventricular system, potentially causing post-hemorrhagic hydrocephalus. PAR
stimulation leads to activation of multiple proliferative signaling pathways, including
PI3K/Akt, MAPK, and mTOR (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et
al. 2005; Luo, Wang et al. 2007). Previously, mTOR inhibition improved long-term brain
morphological and neurofunctional outcomes after GMH, and combinatorial PAR-1,-4
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inhibition reduced mTOR activation at 72 hours post-GMH. Yet, neither mTOR
inhibition, PAR-1,-4 inhibition, nor ECM protein proliferation have been evaluated for
long-term outcomes after GMH (Lekic, Klebe et al. 2015). Herein, p-mTOR expression
was increased immediately following GMH and remained elevated to 7 days, and a
similar trend was observed for p-p70s6k (Figure 5.4). Dabigatran attenuated the elevated
expressions of p-mTOR and p-p70s6k, which was reversed by PAR-1 stimulation. Yet
PAR-1 inhibition alone did not significantly decrease p-mTOR or p-p70s6k (Figure 5.5).
Our results suggest thrombin inhibition decreases mTOR activation, yet is seems that
stimulation of any of thrombin’s downstream PARs is sufficient to increase mTOR
activation. When thrombin is inhibited, it is not able to stimulate PARs inducing mTOR
activation, yet stimulation of one PAR, PAR-1 here, was capable of activating mTOR.
This is supported by the current work that inhibition of only PAR-1 was unable to
prevent mTOR activation. Additionally, this is supported the work of Lekic et al. that
combinational PAR-1,-4 inhibition reduced p-mTOR expression 72 hours after GMH,
indicating that combinatorial PAR inhibition may be necessary to completely target this
pathway.
Activated mTOR is hypothesized to contribute towards long-term ECM protein
proliferation, which was observed in this work. Dabigatran (intraperitoneally and
intranasally) significantly decreased vitronectin and fibronectin, and PAR-1 agonist coadministration did not reverse Dabigatran’s effects on vitronectin expression but tended
to reverse fibronectin expression. PAR-1 inhibition alone tended to reduce vitronectin
and fibronectin (Figure 5.6). Long-term ECM protein proliferation weakly correlates with
short-term p-mTOR expression levels, suggesting PAR-1/mTOR plays a small role, but
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other signaling pathways must be involved as well. Most importantly, ECM protein
proliferation does not strongly correlate with brain morphological and intracranial
pressure outcomes, but p-mTOR expression levels do correlate, suggesting future
investigations into post-GMH hydrocephalus development should focus less on ECM
protein proliferation and more on alternative p-mTOR-related pathways, particularly
active mTOR’s relationship with immunomodulatory and cell survival pathways.
Our study has some limitations that need to be considered. First, neither the time
course of Dabigatran plasma concentrations after intranasal injection, nor the time course
of Dabigatran brain levels after intraperitoneal or intranasal administration. Second, the
effects of intranasal Dabigatran on hematoma volume were also not examined, nor was a
dosing study on intranasal Dabigatran performed. Third, thrombin has a plethora of
downstream targets in addition to PAR/mTOR-induced ECM proliferation, including
immunomodulatory and cell survival pathways (Krenzlin, Lorenz et al. 2016).The scope
of this study was on PAR-1/mTOR to isolate a potentially effective pathway downstream
of thrombin which may play an important role in post-hemorrhagic hydrocephalus
development. PAR-1 agonist and antagonist effects should also be interpreted cautiously,
since PAR-1 exhibits biased agonism and responds to various doses of drugs and stimuli
differently (Mosnier, Sinha et al. 2012). Fourth, some evidence suggests plasma
fibronectin and vitronectin leak into the brain tissue following hemorrhagic
transformation after ischemia in adult mice, indicating another source of ECM proteins in
addition to those produced from fibrosis (del Zoppo, Frankowski et al. 2012). Increased
long-term ECM protein expression after GMH, however, may depend more on chronic
fibrosis than acute vascular extravasation. Fifth, the therapeutic window for post-GMH
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treatments is poorly defined due to lack of clinically approved or tested therapies, and the
initial two hour post-ictus treatment time point examined may be too narrow for clinical
translation. Finally, although our model produces consistent hemorrhages with
consequent gliosis, neurological deficits, white matter loss, brain atrophy, and posthemorrhagic hydrocephalus consistent with human neonatal brain hemorrhage, vascular
integrity is disrupted by direct protease infusion (Lekic, Manaenko et al. 2012), which
does not perfectly model GMH pathophysiology caused by hemodynamic, microvascular,
and cardiorespiratory instability emulated in other animal models (Chua, Chahboune et
al. 2009; Yang, Baumann et al. 2013). These limitations will be the focus of future
studies.

Conclusions
Direct thrombin inhibition by Dabigatran decreased acute mTOR activation,
reduced long-term ECM protein proliferation, ameliorated post-hemorrhagic
hydrocephalus development, and improved long-term neurofunctional outcomes.
Inhibition of PAR-1, a thrombin downstream receptor, was not sufficient to achieve the
same observed therapeutic effectiveness as direct thrombin inhibition by Dabigatran. Yet
PAR-1 stimulation tended to reverse Dabigatran’s therapeutic effects on long-term posthemorrhagic hydrocephalus development and short-term mTOR activation, suggesting a
role for PAR-1 in GMH sequelae. Future investigations should employ combinatorial
PAR-1, -3, and/or -4 inhibition treatment modalities and further investigate additional
pathways related to thrombin and active mTOR, including inflammatory and cell survival
pathways.
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CHAPTER SIX
DISCUSSION AND CONCLUSION

Summary/Highlights of Findings
Our findings demonstrate blood, iron, and thrombin/PAR-1/mTOR activation
contribute to GMH-induced brain injury and long-term PHH development. These
findings are supported by the following observations: (1) PPARγ-induced upregulation of
CD36 enhances short-term hematoma resolution and attenuates long-term neurological
deficits and brain morphological outcomes; (2) acute and delayed iron chelation by
Deferoxamine improves long-term brain morphological and neurobehavioral outcomes as
well as reduced ECM protein proliferation; (3) combinatorial PAR-1 and PAR-4
inhibition reduced short-term COX-2 and mTOR activation, and COX-2 and mTOR
inhibition improved long-term brain morphological and neurocognitive outcomes; (4)
direct thrombin inhibition by Dabigatran reduces short-term mTOR activation and
ameliorates long-term PHH development and neurocognitive deficits, which was not
reversed by PAR-1 stimulation, nor could PAR-1 inhibition alone achieve the same
therapeutic benefits as direct thrombin inhibition.

The State of the Field Prior to this Study
The pathophysiological mechanisms leading to PHH development after GMH
remain to be clearly elucidated. Thrombin, intracerebroventricular blood clots, and iron
have been identified as potentially causative factors of hydrocephalus formation.
Thrombin initiates inflammatory responses, gliosis, and ECM protein proliferation that
potentially obstruct the cerebroventricular system (Whitelaw 2001; Xue,
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Balasubramaniam et al. 2003; Cherian, Whitelaw et al. 2004; Volpe 2009; Aquilina,
Chakkarapani et al. 2011). Thrombin activates PARs, which subsequently activate
downstream mTOR. Activation of mTOR is associated with ECM protein proliferation
and impaired CSF dynamics (Paul, Leef et al. 2000; Kataoka, Hamilton et al. 2003;
Crews, Wyss-Coray et al. 2004; Del Bigio 2004; Steinhoff, Buddenkotte et al. 2005; Xue
and Del Bigio 2005; Ballabh, Xu et al. 2007; Dummula, Vinukonda et al. 2010). PPARγ
stimulation enhances CD36 scavenger receptor-mediated microglial phagocytosis of red
blood cells, resulting in increased clot resolution and improved outcomes after adult
cerebral hemorrhage (Zhao, Zhang et al. 2006; Zhao, Sun et al. 2007). Iron chelation also
improved adult cerebral hemorrhage outcomes (Hatakeyama, Okauchi et al. 2013).
Pharmacological modulation of the thrombin/PAR/mTOR pathway, PPARγ, and iron,
which all have clinically translatable pharmacological agents that target them available,
for neonatal GMH have not been studied. A safe and non-invasive treatment for reducing
PHH would significantly improve the quality of life for GMH patients.

How Our Findings Advance the Field
The findings from this investigation further elucidate some of the underlying
pathophysiological mechanisms contributing to PHH development after GMH. In
particular, we investigate the role of thrombin/PAR-1/mTOR, PPARγ/CD36, and iron.
Our study suggests some therapeutic benefit can be achieved by a clinically available
direct thrombin inhibitor, Dabigatran. Since thrombin inhibition has the risk of increased
bleeding, investigating downstream thrombin pathways may provide more safe
therapeutic alternatives. Thrombin inhibition ameliorated long-term PHH, neurological
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deficits, and ECM protein proliferation as well as decreased short-term mTOR activity
after GMH. Interestingly, PAR-1 inhibition alone did not achieve the same therapeutic
benefits as thrombin inhibition, nor did PAR-1 stimulation reverse all therapeutic effects
from thrombin inhibition, although brain morphological outcomes and mTOR activity
were reversed. PAR-1 inhibition also tended to decrease ECM protein proliferation while
PAR-1 stimulation only tended to reverse ECM protein proliferation. Interestingly,
combinatorial PAR-1 and PAR-4 inhibition reduced short-term mTOR activity,
suggesting inhibiting one PAR is not sufficient to diminish activity of downstream
effectors. Future studies should investigate long-term combinatorial inhibition of PARs
after GMH. Our findings suggest ECM protein proliferation is weakly associated with
long-term PHH development. Furthermore, two Dabigatran administration routes were
investigated, intraperitoneal and intranasal, and both achieved the same therapeutic
benefits.
Our findings also suggest enhancing hematoma resolution by stimulating PPARγ,
which can be targeted by clinically available pharmacological agents, such as
thiazolidinediones, enhances short-term hematoma resolution and improves long-term
brain morphological and neurocognitive outcomes after GMH. PPARγ antagonization
reversed treatment effects, and CD36 knockdown also reversed PPARγ agonist effects on
short-term hematoma resolution. Enhanced hematoma resolution was associated with
increased presence of alternatively activated M2 microglia/macrophages, suggesting
PPARγ stimulation modulates microglia/macrophage differentiation. In addition to
enhancing clot resolution, removing iron released from lysed erythrocytes by
administering a clinically available iron chelator, Deferoxamine, also ameliorated long-
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term PHH, improved neurocognitive function, and reduced ECM proliferation.
Therapeutic benefits were achieved when Deferoxamine was administered within hours
after GMH as well as three days after GMH, suggesting iron chelation has a large
therapeutic window. Our findings provide pertinent information regarding clinically
viable therapeutic targets to attenuate long-term PHH development after GMH.

Summary/Conclusion
Direct thrombin inhibition, enhanced hematoma resolution by PPARγ stimulation,
and iron chelation all resulted in improved long-term brain morphological (i.e. reduced
PHH) and neurocognitive outcomes after experimental GMH in rat pups. Direct thrombin
inhibition and combinatorial PAR-1 and PAR-4 inhibition resulted in decreased shortterm p-mTOR expression. PAR-1 inhibition alone did not decrease p-mTOR activity,
although PAR-1 stimulation with direct thrombin inhibition reversed treatment effects by
increasing p-mTOR activity. Rapamycin treatment to inhibit mTOR improved brain
morphological and neurocognitive outcomes. Direct thrombin inhibition reduced longterm intracranial pressure, improved brain morphological outcomes, ameliorated
neurological deficits, and reduced ECM protein proliferation, but PAR-1 inhibition alone
did not achieve the same therapeutic benefits although ECM protein proliferation tended
to be reduced. Additionally, PAR-1 stimulation with direct thrombin inhibition only
tended to reverse treatment effects on brain morphological outcomes, intracranial
pressure, and ECM protein proliferation. Short-term mTOR activity is strongly associated
with PHH development after GMH, and ECM protein proliferation is weakly associated
with PHH. Additionally, PPARγ stimulation enhanced short-term hematoma resolution,
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which was reversed by PPARγ antagonism and CD36 knockdown. PPARγ stimulation
improved long-term neurocognitive and brain morphological outcomes, which was
reversed by PPARγ antagonism. Iron chelation starting immediately after GMH and 72
hours after GMH improved long-term brain morphology, reduced neurocognitive deficits,
and diminished ECM protein proliferation. Thus, the thrombin/PAR/mTOR pathway, the
PPARγ/CD36 pathway, and iron play significant roles in long-term PHH development
after GMH.

Prospective
Although our findings show blood clots, iron, and the thrombin/PAR/mTOR
pathway play important roles in PHH development after GMH, it cannot concluded if
PHH developed because of an obstruction in the cerebroventricular system and/or
subarachnoid spaces. Indeed, current hydrodynamic theory of CSF dynamics and
hydrocephalus development suggests the source for CSF production is choroidal and
ependymal capillaries and the source for CSF reabsorption is subarachnoid and
parenchymal capillaries as well as perivascular channels following glymphatic-mediated
CSF-interstitial fluid exchange. Hydrocephalus results from a disruption in hydrostatic
and oncotic pressures in the brain microvasculature as well as possible abnormal
distribution of vascular pulsations due to changes in brain compliance (Egnor, Zheng et
al. 2002; Greitz 2004; Oreskovic and Klarica 2011; Iliff, Wang et al. 2012). Further
investigations into PHH development after GMH should focus less on possible
cerebroventricular obstructions and more on alterations in barrier mechanisms of the
brain microvasculature as well as the glymphatic system.
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Abstract
Cerebral hemorrhages account for 15-20% of stroke sub-types and have very poor
prognoses. The mortality rate for cerebral hemorrhage patients is between 40-50%, of
which at least half of the deaths occur within the first two days, and 75% of survivors are
incapable of living independently after one year. Current emergency interventions
involve lowering blood pressure and reducing intracranial pressure by controlled
ventilations or, in the worst case scenarios, surgical intervention. Some hemostatic and
coagulatherapeutic interventions are being investigated, although a few that were
promising in experimental studies have failed in clinical trials. No significant
immunomodulatory intervention, however, exists for clinical management of cerebral
hemorrhage. The inflammatory response following cerebral hemorrhage is particularly
harmful in the acute stage because blood-brain barrier disruption is amplified and
surrounding tissue is destroyed by secreted proteases and reactive oxygen species from
infiltrated leukocytes. In this review, we discuss both the destructive and regenerative
roles the immune response play following cerebral hemorrhage and focus on microglia,
macrophages, and T-lymphocytes as the primary agents directing the response.
Microglia, macrophages, and T-lymphocytes each have sub-types that significantly
influence the over-arching immune response towards either a pro-inflammatory,
destructive, or an anti-inflammatory, regenerative, state. Both pre-clinical and clinical
studies of cerebral hemorrhages that selectively target these immune cells are reviewed
and we suggest immunomodulatory therapies that reduce inflammation, while
augmenting neural repair, will improve overall cerebral hemorrhage outcomes.
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Cerebral Hemorrhage Pathophysiology
Incidence, Outcomes, and Clinical Management
Cerebral hemorrhage, the rupturing of blood vessels within the brain tissue,
accounts for 10-15% of strokes (Qureshi, Mendelow et al. 2009; Mracsko and Veltkamp
2014). Occurring in approximately 25 per 100,000 people per year, cerebral hemorrhage
is the leading cause of morbidity and mortality in stroke patients, having a mortality rate
between 30-50% with nearly 75% of survivors incapable of living independently after
one year (van Asch, Luitse et al. 2010). Hospital admissions for cerebral hemorrhage
cases have increased by 18% over the past decade, and admissions are expected to
continue rising due to an increasing elderly population (Qureshi, Mendelow et al. 2009).
Current clinically approved emergency interventions involve lowering blood
pressure (Anderson, Huang et al. 2008; Morgenstern, Hemphill et al. 2010; Sakamoto,
Koga et al. 2013) or surgical craniotomy (Morgenstern, Hemphill et al. 2010).
Hematoma evacuation is also being investigated as a potential surgical intervention, but it
has yet to yield positive results (Morgenstern, Frankowski et al. 1998; Mendelow,
Gregson et al. 2005; Miller, Vespa et al. 2008; Wang, Jiang et al. 2009; Mendelow,
Gregson et al. 2013). Hemostatic therapies have also been investigated in clinical trials,
such as recombinant factor VII, but despite showing promise in experimental studies,
none have been clinically approved (Mayer, Brun et al. 2006; Mayer, Brun et al. 2008;
Diringer, Skolnick et al. 2010). Unfortunately, cerebral hemorrhage is the least treatable
stroke subtype, with minimal advancements being made in clinical management, despite
its increasing prevalence (Kreitzer and Adeoye 2013).

164

Primary Brain Injury
Most investigative therapeutic approaches for cerebral hemorrhage focus on
ameliorating primary brain injury, which is caused by the mechanical pressure on brain
tissue due to the hematoma mass effect, and the potential hematoma expansion (Xi, Keep
et al. 2006; Keep, Hua et al. 2012; Mracsko and Veltkamp 2014). Mechanical pressure
applied to glia and neurons cause calcium influx and secretion of excitotoxic
neurotransmitters, resulting in consequent cytotoxic edema and necrosis (Keep, Xi et al.
2005; Xi, Keep et al. 2006). Indeed, hematoma volume and subsequent hematoma
expansion, which occurs in approximately 30% of clinical cerebral hemorrhage cases, are
currently the best prognostic indicators (Davis, Broderick et al. 2006; Dowlatshahi,
Demchuk et al. 2011; Brouwers and Greenberg 2013). Brain edema, caused by both
primary and secondary brain injury mechanisms, is increasingly accepted as a valuable
prognostic indicator (Thiex and Tsirka 2007; Staykov, Wagner et al. 2011).

Secondary Brain Injury
Mechanisms for secondary brain injury after cerebral hemorrhage have garnered
increased research interests over the past decade. Secondary brain injury results from
blood components entering the brain tissue as well as injured brain cells that trigger
multiple deleterious mechanisms and subsequently augment oxidative stress,
inflammatory pathways, blood-brain barrier disruption, and vasogenic edema (Aronowski
and Zhao 2011; Belur, Chang et al. 2013). Coagulation cascade activation increases
thrombin formation, which stimulates the complement pathway as well as proteaseactivated receptors (PARs) (Hua, Keep et al. 2007; Babu, Bagley et al. 2012). PAR
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stimulation after hemorrhage, particularly PAR-1 activation in neurons, leads to increased
NMDA receptor potentiation and consequent activation of excitotoxicity, apoptosis, and
pro-inflammatory pathways (Babu, Bagley et al. 2012). PAR-1 has also been implicated
in playing an important role in thrombin-induced cerebral hemorrhaging (Cheng, Xi et al.
2014). Complement activation after cerebral hemorrhage leads to membranous pore
formation, called membrane attack complexes, in neurons and red blood cells, causing
cytotoxicity and cell lysis (Hua, Xi et al. 2000; Ducruet, Zacharia et al. 2009).
Red blood cell lysis releases hemoglobin, which is metabolized by heme
oxygenase 1 to release iron and heme, into the surrounding tissue (Wu, Xi et al. 2006).
Heme and iron are critical constituents in redox reactions that produce injurious free
radicals and increase oxidative stress, causing significant tissue injury, DNA damage,
blood-brain barrier disruption, and inflammation (Wu, Xi et al. 2006; Xi, Keep et al.
2006; Babu, Bagley et al. 2012; Xiong, Wang et al. 2014). Administering Deferoxamine,
an iron chelator, resulted in improved neurofunctional outcomes following experimental
cerebral hemorrhage and reduced hydrocephalus development in other brain injury
models (Nakamura, Keep et al. 2004; Klebe, Krafft et al. 2014; Zhao, Chen et al. 2014).
Indeed, post-hemorrhagic hydrocephalus is a common consequence of intracerebral
hemorrhage as well, and iron has been implicated as a causative factor (Chen, Zhang et
al. 2014; Gao, Du et al. 2014; Meng, Li et al. 2014).
Inflammation is a key component of secondary brain injury following cerebral
hemorrhage (Wang 2010; Mracsko and Veltkamp 2014; Zhou, Wang et al. 2014; Chen,
Yang et al. 2015). An inflammatory response ensues immediately after blood enters the
brain tissue via activation of resident immune cells and subsequent infiltration of
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peripheral leukocytes, leading to secretion of pro-inflammatory mediators, extracellular
proteases, and reactive oxygen species that further damage brain tissue and disrupt the
blood-brain barrier (Aronowski and Hall 2005; Wang and Dore 2007). Immune cells,
particularly pro-inflammatory macrophages, also play an important role in cerebral
aneurysm formation, a primary cause for cerebral hemorrhage (Hosaka and Hoh 2014;
Starke, Raper et al. 2014). Some evidence, however, suggests inflammation may play an
important role in repair and recovery following central nervous system injury (Correale
and Villa 2004; Hohlfeld, Kerschensteiner et al. 2006; McCombe and Read 2008; Wee
Yong 2010). The potential neuroprotective branch in inflammation may be
therapeutically exploited following cerebral hemorrhage to promote hematoma resolution
as well as tissue repair and regeneration.

Review Scope
In this review, we will discuss microglia, macrophage, and T-helper lymphocyte
immunology following cerebral hemorrhagic insult, the roles which the subtypes for each
play in neurodegeneration or neuroprotection, as well as possible therapeutic approaches
to potentially shift the inflammatory response towards a neuroregenerative phenotype.
We will also discuss evidence from current cerebral hemorrhage research and address
gaps in the literature that warrant further investigation. Explicating the immune response
in its entirety following cerebrovascular insult will discern therapeutic
immunomodulatory approaches that dampen the neurodegenerative inflammatory
response in favor for a neuroregenerative one, promoting functional recovery and
improving overall outcomes. Cerebral hemorrhage pathophysiology is very complex and
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multi-modal approaches are being increasingly encouraged, and exploiting
immunomodulatory mechanisms may prove beneficial when investigating such
approaches since inflammation is an important component of secondary brain injury
(Pandey and Xi 2014).

Macrophage, Microglia, and T-helper Lymphocyte Characterization
Macrophage and Microglia Subtypes
Macrophages are a type of white blood cell of myeloid lineage found in almost all
tissue types and play a quintessential role in innate (non-specific) immunity by searching
for and engulfing potential pathogens (Murray and Wynn 2011). Microglia are the
resident macrophages of the central nervous system, and, unfortunately, they are
extremely difficult to distinguish from infiltrated macrophages following central nervous
system injury (Saijo and Glass 2011). Traditionally, macrophages and microglia
phagocytose microbes, cellular debris, apoptotic cells, cancer cells, and foreign
substances. Stimulation of microglia/macrophage toll-like receptors, nod-like receptors,
scavenger receptors, and/or cytokine receptors from inflammatory cytokines, pathogens,
and blood products will potentiate the inflammatory response through further secretion of
pro-inflammatory cytokines, such as TNF-α and IL-1β, resulting in leukocyte
recruitment. Recent immunology research, however, discerned macrophages can also
dampen the immune response, promoting tissue repair and regeneration. Microglia and
macrophages have been classified into two predominant subtypes modeled similar to the
Th1/Th2 paradigm: classically activated or M1 and alternatively activated or M2 (Murray
and Wynn 2011; Saijo and Glass 2011). Further elucidating the role each subtype plays
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in cerebral hemorrhage pathophysiology may yield potential therapeutic avenues that
coax the immune response to create a neural regenerative milieu in the peri-hematoma
region.
Classically activated M1 macrophages and microglia are primarily responsible for
the innate immune defense mechanisms, producing a pro-inflammatory response (Murray
and Wynn 2011; Saijo and Glass 2011). The M1 phenotype can be induced by
lipopolysaccharides, interferon-γ, TNF-α, or stimulation of nod-like receptors (NLR) or
toll-like receptors (TLR), primarily TLR-4 (Martinez, Helming et al. 2009; Chen and
Nunez 2010). Very few definitive cell surface markers for the M1 subtype have been
identified, although CD80 and CD86 are widely used. M1 macrophages and microglia
also secrete TNF-α, IL-1β, IL-6, IL-12, and IL-23 pro-inflammatory cytokines (Martinez
and Gordon 2014; Wang, Liang et al. 2014). Alternatively, activated M2 macrophages
and microglia are primarily responsible for mediating wound healing and produce an
anti-inflammatory response (Murray and Wynn 2011; Saijo and Glass 2011). The M2
phenotype can be induced by IL-4, IL-10, TGF-β, and IL-13 stimulation (Martinez,
Helming et al. 2009; Martinez and Gordon 2014; Wang, Liang et al. 2014). Common
cell surface markers attributed to the M2 subtype include CD163 and CD206, and M2
macrophages and microglia secrete IL-10 and TGF-β anti-inflammatory cytokines
(Martinez, Helming et al. 2009; Martinez and Gordon 2014; Wang, Liang et al. 2014).
Evidence suggests macrophages and microglia do not exist as terminally differentiated
M1 or M2 states, but rather have the ability to switch phenotypes depending upon their
microenvironment (Stout and Suttles 2004; Stout, Jiang et al. 2005; Eggen, Raj et al.
2013; Giunti, Parodi et al. 2014). Table A.1 contains the macrophage/microglia
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subtypes, cytokines inducing their activation, common markers, secreted cytokines, as
well as known mechanisms of action.
The M1/M2 paradigm, however, has limitations. Indeed, M2 microglia are being
further classified into 3 subsets based on how differentiation is stimulated: M2a is
stimulated by IL-4 and IL-10; M2b is stimulated by toll-like receptor activation; and M2c
is stimulated by IL-10, glucocorticoids, and TGF-β (Cherry, Olschowka et al. 2014).
M2a and M2c have the typical markers and responses attributed to alternatively activated
M2, while M2b lacks certain markers and has a response similar to M1 (Cherry,
Olschowka et al. 2014). Additionally, An increasing number of macrophage/microglia
subsets in addition to M1/M2 are being classified in other diseases and disorders, such as
atherosclerosis, multiple sclerosis, and lupus, including M4, Mox, Mhem, and M(Hb)
(Orme and Mohan 2012; Bogie, Stinissen et al. 2014; Chinetti-Gbaguidi, Colin et al.
2015). Furthermore, distinct macrophage/microglia responses have been characterized in
vitro following stimulation by cytokines and extracellular pathogenic debris as well as in
vivo following infection, yet the exact roles distinct microglia/macrophage subtypes play
in most neurological diseases, disorders, and injuries have yet to be well elucidated. M1
and M2 may represent two extremes on a large spectrum of macrophage/microglia
subsets where each subset plays a very critical immunomodulatory role in cerebral
hemorrhage pathophysiology, and more research is needed to fill these gaps in our
knowledge and help advance immunotherapeutic approaches.
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Table A.1: Macrophage/Microglia and T-helper Lymphocyte Subtypes
Cell Activating
Types Cytokines

M1

M2

Th1

Th2

Markers

Secreted
Cytokines

Mechanisms of action

CD86,
CD80, MHC
IFN-γ, TNFTNF-α, IL- Inhibits cell proliferation and
II↑, IL-1R I,
α, LPS
12, and IL-23 causes tissue damage
TLR2,
TLR4, iNOS
CD163,
MHC II,
SR, CD206↑,
(MR↑),
IL-10, TGFPromotes cell proliferation
IL-4, IL-13 TGM2↑,
β, and ILand tissue repair
DecoyR, IL- 1RA
1R II,
Ym1, Fizz1,
Arg-1
Activate macrophages and
CD4,
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T-helper Lymphocyte Subtypes
T-helper cells are CD4+ white blood cells of lymphoid origin that develop within
the thymus which are critical in regulating cell-mediated and adaptive immunity
(Luckheeram, Zhou et al. 2012). The two predominant paradigms for T-helper cell
subtypes, analogous to the M1/M2 macrophage and microglia paradigm in that the two
phenotypes oppose each other, are Th1/Th2 and Th17/Treg (Kleinewietfeld and Hafler
2013; Bretscher 2014). Macrophages and microglia are capable of switching phenotypes
according to their microenvironment, and some evidence supports T-helper cells
switching phenotypes too, particularly between Th17 and Treg, although more conclusive
evidence is needed (Stout and Suttles 2004; Stout, Jiang et al. 2005; Xu, Kitani et al.
2007; Kleinewietfeld and Hafler 2013).
Th1 cells direct the immune system towards fighting intracellular pathogens by
inducing a cell-mediated response. Th1 cell differentiation is kindled by IL-12 and
interferon-γ stimulation, the latter of which Th1 cells secrete to further drive Th1
differentiation. Th2 cells direct the immune system towards fighting extracellular
pathogens by inducing a humoral response. Th2 cell differentiation is sparked by IL-4
and IL-2 stimulation, and Th2 cells secrete IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 (Zhu
and Paul 2008; Zhu and Paul 2010; Luckheeram, Zhou et al. 2012). Th1 cells are
characterized by CCR5, CXCR3, and T-bet markers, while Th2 cells are identified by
CCR3, CCR4, CRTH2, and GATA3 markers. Th1 and Th2 both drive their own
differentiation while suppressing differentiation into the other through their cytokine
expressions (Zhu and Paul 2008; Zhu and Paul 2010; Luckheeram, Zhou et al. 2012).
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The other T-helper phenotype paradigm relies on the promotion or suppression of
inflammation. Th17 cells which potentiate inflammation and have been implicated as
potential sources for many autoimmune diseases differentiate through IL-6, IL-21, IL-23,
and TGF-β stimulation. T17 cells, which express CCR6 and RORγt markers, secrete IL17, IL-21, and IL-22 (Stockinger and Veldhoen 2007; Dong 2008; Hirota, Martin et al.
2010; Peck and Mellins 2010; Dong 2011). Treg cells which dampen inflammation and
mediate immune tolerance to self-antigens, differentiate through IL-2 and TGF-β
stimulation (Chen, Jin et al. 2003; Mantel and Schmidt-Weber 2011; Yoshimura and
Muto 2011). Treg cells, characterized by CD25 and FOXP3 markers, secrete IL-10 and
TGF-β. Evidence suggests plasticity between Th17 and Treg cell differentiation, which
is highly dependent upon their surrounding milieu (Zhou, Chong et al. 2009;
Kleinewietfeld and Hafler 2013). Interestingly, differentiation of both Th17 and Treg
cells can be driven by TGF-β (Li, Wan et al. 2007). TGF-β at low concentrations and in
conjunction with IL-6 or IL-21 will drive Th17 differentiation, but TGF-β at high
concentrations and in conjunction with IL-10 will drive Treg differentiation (Chen, Jin et
al. 2003; Mantel and Schmidt-Weber 2011; Yoshimura and Muto 2011). Table A.1
contains the T-helper lymphocyte subtypes, cytokines inducing their activation, common
markers, secreted cytokines, as well as known mechanisms of action.

Macrophage/Microglia and T-helper Lymphocyte Communication
T-helper lymphocytes, macrophages, and microglia are capable of influencing
each other’s differentiation as well as phenotype switching (Murray and Wynn 2011;
Saijo and Glass 2011; Luckheeram, Zhou et al. 2012). M1 macrophages secrete TNF-α,

173

IL-6, IL-12, and IL23 (Murray and Wynn 2011; Saijo and Glass 2011), which recruits
and induces differentiation of both Th1 and Th17 cells. In turn, Th1 cells secrete
interferon-γ while Th17 cells secrete IL-17, which further augments M1 macrophage
polarization and potentiates the inflammatory response (Fiorentino, Zlotnik et al. 1991;
Denning, Wang et al. 2007; Martinez, Sica et al. 2008; Savage, de Boer et al. 2008;
Biswas and Mantovani 2010). M1 macrophage and Th1 / Th17 cross-talk acts as a
positive feed-back loop that further drives their own differentiation and create a highly
inflamed microenvironment. Analogously, M2 macrophages secrete IL-4, IL-10, and
TGF-β (Martinez, Sica et al. 2008; Murray and Wynn 2011; Saijo and Glass 2011),
which recruits and induces differentiation of both Th2 and Treg cells. In turn, Th2 cells
secrete IL-4 and IL-10 while Tregs secrete IL-10 and TGF-β, which further drives M2
polarization, dampening inflammation and promoting tissue repair (Denning, Wang et al.
2007; Martinez, Sica et al. 2008; Savage, de Boer et al. 2008; Biswas and Mantovani
2010). Disproportion between macrophage/microglia and T-helper cells, in which either
the M1/Th1/Th17 or M2/Th2/Treg branches are overexpressed, intensify many disorders,
including allergies, asthma, cancer, autoimmune diseases, atherosclerosis, and fibrosis.
Consequently, many therapeutic approaches have been developed to exploit the cross-talk
between macrophages/microglia and T-helper cells, restoring homeostasis between proinflammatory and regenerative signaling in those aforementioned disorders (Murray and
Wynn 2011; Saijo and Glass 2011; Luckheeram, Zhou et al. 2012).
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Inflammation after Cerebral Hemorrhage
Role of Macrophages and Microglia
Explicating the inflammatory component of cerebral hemorrhage pathophysiology
and discerning the immune cells involved, particularly the distinct macrophage/microglia
and T-helper cell subsets, could lead to novel therapeutic approaches in which the perihematoma milieu is switched from a pro-inflammatory microenvironment to a
neuroregenerative one. Macrophages, microglia, and T-helper cell subsets are ideal
targets because of the cross-talk and capability of potentiating either the damaging branch
of inflammation via M1/Th1/Th17 or the repair/regenerative branch via M2/Th2/Treg
(Murray and Wynn 2011; Saijo and Glass 2011; Luckheeram, Zhou et al. 2012). The
M1/Th1/Th17 branch creates an oxidative, caustic microenvironment to destroy
pathogens, but cerebral hemorrhage is a brain injury of endogenous origin, thus
attenuating this branch in favor of the M2/Th2/Treg branch may be beneficial (Chen and
Nunez 2010). Macrophages and microglia are of particular interest since they are the
first to be activated following hemorrhage and are quintessential drivers of the immune
response (Mracsko and Veltkamp 2014; Zhou, Wang et al. 2014). Furthermore, microglia
and macrophages have great plasticity and aptly switch phenotypes between M1 and M2
in response to the pathophysiology of their microenvironment.
Activated microglia become present within 1-4 hours after cerebral hemorrhage in
rodents, peak between 3-7 days, and finally return to basal levels between 3-4 weeks
(Wang and Dore 2007; Zhou, Wang et al. 2014). Following microglia activation,
peripheral macrophages also infiltrate the injured tissue, although they are extremely
difficult to distinguish from microglia. Microglia/macrophages also recruit neutrophils
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within hours of activation, which potentiate blood-brain barrier disruption and tissue
damage by secreting extracellular proteases (Wang and Dore 2007; Zhao, Sun et al.
2014). While the activated microglia time course has been established in these
experimental rodent cerebral hemorrhage models, the time course of M1 and M2
phenotype expression has yet to be well-defined. Determining the ratio of M1/M2
microglia and macrophages could be indicative of the pathophysiological milieu, as a
high M1/M2 ratio implies a more oxidative, caustic inflammatory environment while a
low M1/M2 ratio implies a more repair, regenerative environment. M2 microglia and
macrophages have increased scavenger receptor expression levels as well as augmented
phagocytic activity compared to their M1 counterparts, therefore the M2 phenotype may
be important for hematoma resolution after cerebral hemorrhage (Cherry, Olschowka et
al. 2014). Indeed, hematoma volume peaks 72 hours after experimental cerebral
hemorrhage, remains relatively elevated from 3-7 days, and is finally resolved between 24 weeks (Zhao, Grotta et al. 2009). Coincidentally, this correlates with the time course of
activated microglia number, thus elucidating the time course of the M1/M2 ratio
following cerebral hemorrhage may yield more information on the neuroprotective role
microglia and macrophage subtypes play, as it is expected the M1/M2 ratio will rise and
fall with hematoma volume, implying M2 microglia and macrophages are important for
hematoma resolution.
A thoroughly investigated therapy involves enhancing hematoma resolution by
peroxisome proliferator receptor gamma (PPARγ) stimulation. PPARγ stimulation
enhances hematoma resolution, reduces oxidative stress, ameliorates damaging
inflammation, decreases brain edema, and improves functional outcomes starting at 24
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hours after cerebral hemorrhage in experimental rodent models (Zhao, Sun et al. 2007;
Zhao, Grotta et al. 2009). Furthermore, Pioglitazone, a PPARγ agonist, is being
investigated in a clinical trial for enhancing hematoma resolution after cerebral
hemorrhage. PPARγ stimulation upregulates the red blood cell scavenger receptor
CD36, consequently enhancing red blood cell phagocytosis in vitro and in vivo (Zhao,
Sun et al. 2007). Furthermore, the change in the M1/M2 ratio induced by PPARγ
stimulation has not been investigated. However, other studies indicate that PPARγ
stimulation polarizes microglia and macrophages towards the M2 phenotype (Pisanu,
Lecca et al. 2014). Thus the neuroprotective effect from PPARγ treatment may include
polarizing microglia and macrophages towards the M2 phenotype, reducing the M1/M2
ratio, and creating a regenerative peri-hematoma milieu that promotes tissue repair and
hematoma resolution.
After cerebral vessel rupture, damage-associated molecular patterns, molecules
capable of initiating and perpetuating a non-infectious inflammatory response following
injury, stimulate the TLRs and NLRs of microglia, inducing microglia activation (Fang,
Wang et al. 2013). TLR-4 stimulation by damage-associated molecular patterns, in
addition to hemoglobin degradation products, induces M1 differentiation in macrophages
and microglia. In a rodent model of cerebral hemorrhage, TLR-4 knockout mice had
decreased microglia activation and macrophage infiltration at 72 hours post ictus (Fang,
Wang et al. 2013). Additional studies established that TLR-4 blockade also ameliorates
neurological deficits and brain edema after experimental cerebral hemorrhage (Fang,
Wang et al. 2013). While TLR-4 stimulation following cerebral hemorrhage activates
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microglia and induces an M1-like phenotype, the effect on the M2 phenotype is
unknown.
Rather than reduce the M1/M2 phenotype ratio, some studies have aimed at
inhibiting microglia activation altogether. Experimental cerebral hemorrhage studies in
rodents found that microglia inhibitor factor ameliorates brain injury and improves
functional outcomes, which was correlated with overall reduced microglia activation
(Wang and Dore 2007; Zhou, Wang et al. 2014). One such microglia activation inhibitor
is minocycline. Nervous system injury studies discerned minocycline treatment inhibits
M1 microglia and macrophage polarization without affecting M2 polarization. While
preclinical studies have reported that minocycline attenuates brain injury and improves
functional outcomes, one study challenges minocycline’s overall therapeutic potential
(Wang and Dore 2007; Zhou, Wang et al. 2014). Indeed, the authors of a study which
determined that minocycline is neuroprotective also argued that long-term microglia
inhibition may not be beneficial because of the role microglia play in tissue repair,
suggesting that M2 microglia and macrophages may play a long-term neuroprotective
role. This concept may provide an explanation for the results acquired in the negative
minocycline cerebral hemorrhage study. Despite seemingly contradictory studies,
minocycline is currently being evaluated in clinical trials for cerebral hemorrhage.
Evidence provided by other brain injury preclinical models suggests manipulating
M1/M2 polarization by decreasing the M1 phenotype and/or by increasing the M2
phenotype has beneficial outcomes. Although microglia and macrophages are known to
play a very important role in potentiating secondary brain injury after cerebral
hemorrhage, since several studies also suggest they are important for functional recovery,
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little is known about the roles individual microglia subtypes play. Discerning the exact
microglia and macrophage subtypes involved in cerebral hemorrhage pathophysiology, as
well as their time course of action following injury, may yield novel, effective therapeutic
approaches, since decreasing the M1/M2 ratio by either reducing the M1 proinflammatory phenotype and/or increasing the M2 regenerative phenotype may improve
overall outcomes.

Role of T-Helper Lymphocytes
Although cerebral hemorrhage is a brain injury of endogenous origin, and
mounting an antigen specific adaptive immune response may take nearly one week to
occur, increasing evidence suggests that CD4+ T-helper lymphocytes play an important
role in secondary brain injury. Clinical evidence shows the presence of T-helper
lymphocytes within the peri-hematoma region of patients with cerebral hemorrhage
(Guo, Li et al. 2006). Pre-clinical rodent cerebral hemorrhage models indicate T-helper
lymphocyte infiltration is delayed, commencing between 2-4 days post-ictus, yet some
studies have reported T-helper lymphocyte infiltration occurs within one day post-ictus,
peaking at 5 days post-ictus, before subsiding (Mracsko, Javidi et al. 2014). Intuitively,
this suggests T-helper cells, which heavily influence the surrounding milieu of injured
tissue, direct the delayed immune response of cerebral hemorrhage, at least in part, by
encouraging either a highly inflammatory, oxidative microenvironment or a regenerative
and repair microenvironment, although preclinical evidence for the exact role of T-helper
subtypes is lacking.
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Fingolimod, a sphingosine-1 phosphate inhibitor, downregulates sphingosine-1
phosphate receptors in T-helper lymphocytes to reduce their egress from lymphoid tissue
and subsequent infiltration into injured tissue. In a rodent model of cerebral hemorrhage,
fingolimod reduced brain edema and improved neurofunctional outcomes 24 and 72
hours post-ictus, which was associated with reduced T-helper lymphocyte egress in the
blood, decreased T-helper lymphocyte infiltration into the brain, and decreased IL-17
secretion (a pro-inflammatory cytokine typically secreted by Th17 cells (Rolland,
Manaenko et al. 2011; Rolland, Lekic et al. 2013). Fingolimod, however, is known to
upregulate peripheral regulatory T cells with some evidence suggesting it decreases
circulating Th17 cells in clinical and preclinical multiple sclerosis studies. Thus,
Fingolimod’s neuroprotective effects in cerebral hemorrhage may partially be explained
by shifting the predominant T-helper cell response from the inflammatory Th17 subtype
to the regenerative Treg phenotype, although this has yet to be confirmed. Fingolimod is
currently being investigated in clinical trials for cerebral hemorrhage (Fu, Hao et al.
2014).
Another experimental rodent model of cerebral hemorrhage study investigated
adoptive transfer of Treg cells, and observed that Treg cells reduced microglia activation
and improved functional outcomes, however the effects on microglia and macrophage
polarization were not evaluated (Yang, Yu et al. 2014). Furthermore, neural stem cell
transplantation, previously shown to protect the brain from inflammatory damage,
resulted in increased peripheral and infiltrated Treg cells, and was associated with
increased anti-inflammatory cytokines (IL-4, IL-10, and TGF-β) and decreased proinflammatory cytokines (IL-6, interferon-) (Gao, Lu et al. 2014). Furthermore,
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mammalian target of rapamycin (mTOR) inhibition following cerebral hemorrhage in rats
resulted in improved neurofunctional outcomes 24 hours post-ictus which coincided with
increased Treg cells, IL-10, and TGF-β, as well as reduced interferon- in the blood and
brain (Lu, Gao et al. 2014). Unfortunately, investigative studies on the Th1/Th2
paradigm following cerebral hemorrhage are lacking. Yet evidence suggests that
inhibiting Th1 proliferation improves outcomes while inhibiting Th2 aggravates brain
injury during cerebral ischemia (Theodorou, Marousi et al. 2008; Gu, Xiong et al. 2012).
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Table A.2: Current and Past Clinical Trials Evaluating Immunomodulatory Therapies for Cerebral
Hemorrhage
Hemorrhage
type

Agent

Trial

Phase Status

Supratentorial
Intracerebral
Hemorrhage

Prophylactic forced
normothermia

Systemic
Normothermia in
Intracerebral
Hemorrhage (ICH)
(SNICH)

0

Intracerebral
Hemorrhage

The Intracerebral
Hemorrhage Acutely
Labetalol/Hydralazine/Enalapril Decreasing Arterial
2
Pressure Trial II (ICHADAPT II)

Intracerebral
Hemorrhage

Pioglitazone

Intracerebral
Hemorrhage

Minocycline

Intracerebral
Hemorrhage

Intracerebral
hemorrhage

Safety of Pioglitazone
for Hematoma
Resolution In
2
Intracerebral
Hemorrhage
(SHRINC)
A Pilot Study of
Minocycline in
Intracerebral
2
Hemorrhage Patients
(MACH)

References

(Rincon,
Not Yet
Friedman et al.
Recruiting
2014)

(Butcher,
Recruiting Jeerakathil et
al. 2013)

Ongoing

(Gonzales,
Shah et al.
2013)

(Kohler,
Recruiting Prentice et al.
2013)

Rosuvastatin

Effect of Rosuvastatin
in Intracerebral
2
Hemorrhage

(Tapia-Perez,
SanchezComplete
Aguilar et al.
2009)

Nicardipine

IV Double and Triple
Concentrated
4
Nicardipine for Stroke
and ICH

Unknown
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(Koga, Arihiro
et al. 2014)

Conclusion
In this review, we discussed the distinct macrophage and microglia, and T-helper
lymphocyte subtypes, their known roles in cerebral hemorrhage pathophysiology, and
current gaps in the literature. Table A.2 contains a brief overview of current and past
clinical trials investigating immunomodulatory therapies, which are sparse and often
directly target another pathophysiological mechanism with immunomodulation as a
secondary effect. Although many pharmacological approaches showed promise
experimentally, none have thus far successfully translated to the clinic (Ayer, Hwang et
al. 2012). Although the discussion of the M1 and M2 microglia/macrophage subtypes and
the Th1/Th2 and Th17/Treg subtypes is not novel, their unknown roles in cerebral
hemorrhage pathophysiology warrants further investigation as possible therapeutic
targets. Our goal is to advance the discussion of inflammation and secondary brain injury
to involve the distinct immune cell subtypes and their probable neurodegenerative or
neuroprotective roles and encourage further investigation. Indeed, modulating the
immune response by shifting the peri-injury milieu from a highly oxidative, caustic
environment, typically mediated by the M1/Th1/Th17 subtypes, to a regenerative and
repair environment, mediated by the M2/Th2/Treg subtypes, is being increasingly
encouraged in the cerebral ischemia field (Seifert and Pennypacker 2014). Applying the
same concept in polarizing towards a regenerative and repair immune response following
cerebral hemorrhage may yield positive, novel therapeutic approaches, and may be more
desirable than inhibiting inflammation altogether. Applying a multi-modal approach
involving immunomodulatory therapies to ameliorate secondary brain injury in
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conjunction with conventional therapies targeting primary brain injury may improve both
short and long-term outcomes and warrants further investigation.
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